
 
 
 
 
 
 
 
 
 CROSS REFERENCE TO RELATED APPLICATIONS 
 The present application is a national phase application under 35 U.S.C. § 371 of PCT International Application No. PCT/EP2017/060150, filed Apr. 28, 2017, which claims priority to Great Britain Application No. 1607478.3, filed Apr. 29, 2016, each of which are hereby incorporated by reference in its entirety. 
 The present invention relates to conjugates comprising a specific pyrrolobenzodiazepine (PBD), and the precursor drug linker used to make such conjugates. 
 BACKGROUND TO THE INVENTION 
 Some pyrrolobenzodiazepines (PBDs) have the ability to recognise and bond to specific sequences of DNA; the preferred sequence is PuGPu. The first PBD antitumour antibiotic, anthramycin, was discovered in 1965 (Leimgruber, et al.,  J. Am. Chem. Soc.,  87, 5793-5795 (1965); Leimgruber, et al.,  J. Am. Chem. Soc.,  87, 5791-5793 (1965)). Since then, a number of naturally occurring PBDs have been reported, and over 10 synthetic routes have been developed to a variety of analogues (Thurston, et al.,  Chem. Rev.  1994, 433-465 (1994)). Family members include abbeymycin (Hochlowski, et al.,  J. Antibiotics,  40, 145-148 (1987)), chicamycin (Konishi, et al.,  J. Antibiotics,  37, 200-206 (1984)), DC-81 (Japanese Patent 58-180 487; Thurston, et al.,  Chem. Brit.,  26, 767-772 (1990); Bose, et al.,  Tetrahedron,  48, 751-758 (1992)), mazethramycin (Kuminoto, et al.,  J. Antibiotics,  33, 665-667 (1980)), neothramycins A and B (Takeuchi, et al.,  J. Antibiotics,  29, 93-96 (1976)), porothramycin (Tsunakawa, et al.,  J. Antibiotics,  41, 1366-1373 (1988)), prothracarcin (Shimizu, et al,  J. Antibiotics,  29, 2492-2503 (1982);  Langley and Thurston, J. Org. Chem.,  52, 91-97 (1987)), sibanomicin (DC-102)(Hara, et al.,  J. Antibiotics,  41, 702-704 (1988); Itoh, et al.,  J. Antibiotics,  41, 1281-1284 (1988)), sibiromycin (Leber, et al.,  J. Am. Chem. Soc.,  110, 2992-2993 (1988)) and tomamycin (Arima, et al.,  J. Antibiotics,  25, 437-444 (1972)). PBDs are of the general structure: 
 
 
 
 
   
   
 
 
 
 They differ in the number, type and position of substituents, in both their aromatic A rings and pyrrolo C rings, and in the degree of saturation of the C ring. In the B-ring there is either an imine (N═C), a carbinolamine(NH—CH(OH)), or a carbinolamine methyl ether (NH—CH(OMe)) at the N10-C11 position which is the electrophilic centre responsible for alkylating DNA. All of the known natural products have an (S)-configuration at the chiral C11a position which provides them with a right-handed twist when viewed from the C ring towards the A ring. This gives them the appropriate three-dimensional shape for isohelicity with the minor groove of B-form DNA, leading to a snug fit at the binding site (Kohn, In  Antibiotics III . Springer-Verlag, New York, pp. 3-11 (1975); Hurley and Needham-VanDevanter,  Acc. Chem. Res.,  19, 230-237 (1986)). Their ability to form an adduct in the minor groove, enables them to interfere with DNA processing, hence their use as antitumour agents. 
 It has been previously disclosed that the biological activity of this molecules can be potentiated by joining two PBD units together through their C8/C′-hydroxyl functionalities via a flexible alkylene linker (Bose, D. S., et al.,  J. Am. Chem. Soc.,  114, 4939-4941 (1992); Thurston, D. E., et al.,  J. Org. Chem.,  61, 8141-8147 (1996)). The PBD dimers are thought to form sequence-selective DNA lesions such as the palindromic 5′-Pu-GATC-Py-3′ interstrand cross-link (Smellie, M., et al.,  Biochemistry,  42, 8232-8239 (2003); Martin, C., et al.,  Biochemistry,  44, 4135-4147) which is thought to be mainly responsible for their biological activity. 
 One example of a PBD dimer is SG2000 (SJG-136): 
                     
(Gregson, S., et al.,  J. Med. Chem.,  44, 737-748 (2001); Alley, M. C., et al.,  Cancer Research,  64, 6700-6706 (2004); Hartley, J. A., et al.,  Cancer Research,  64, 6693-6699 (2004)) which has been involved in clinical trials as a standalone agent, for example, NCT02034227 investigating its use in treating Acute Myeloid Leukemia and Chronic Lymphocytic Leukemia (see: https://www.clinicaltrials.gov/ct2/show/NCT02034227).
 
 Dimeric PBD compounds bearing C2 aryl substituents, such as SG2202 (ZC-207), are disclosed in WO 2005/085251: 
                     
and in WO2006/111759, bisulphites of such PBD compounds, for example SG2285 (ZC-423):
 
 
 
 
 
   
   
 
 
 
 These compounds have been shown to be highly useful cytotoxic agents (Howard, P. W., et al.,  Bioorg. Med. Chem . (2009), doi: 10.1016/j.bmcl.2009.09.012). 
 WO2010/043880 discloses PBD dimers bearing a anchor for the attachment of another moiety, and WO2011/130613 discloses the use of such modified PBD dimers in antibody drug conjugates. One of the conjugates disclosed, that comprising: 
                     
(termed SGN-CD33A) is undergoing clinical trials in patients with CD33-Postiive Acute Myeloid Leukemia (AML). The pre-clinical development of SGN-CD33A is described in Kung Sutherland, M., et al.,  Blood,  2013; 122(8) 1455-1463 (doi:10.1182/blood-2013-03-491506). An initial report of the clinical trials was provided at the 56 th  ASH Annual Meeting, 6-9 Dec. 2014 (Stein, E., et al., Session 616—Abstract 623).
 
 More recent publications have described the following conjugates comprising PBD dimers, for example, WO2014/057073 describes: 
                     
and WO2015/052321 describes:
 
 
 
 
 
   
   
 
 
 
 DISCLOSURE OF THE INVENTION 
 The present inventors have developed a further drug linker and conjugate comprising said drug linker. This drug linker has an additional aromatic fluoro atom on the C2 methoxyphenyl group, which increases the Log P compared to the drug linker present in SGN-CD33A. Such an increase in Log P would be expected to make the drug linker and its conjugates more hydrophobic and more aggregative, and hence less active. Surprisingly, this does not appear to be the case in vivo. 
 Furthermore, the conjugates of the newly developed drug linker appear to show a reduced activity in vitro to those including the drug linker from SGN-CD33A, which would discourage further testing, but a surprising comparable in vivo activity. 
 In a first aspect, the present invention provides Conjugates of formula I:
 
L-(D L ) p   (I)
 
wherein L is a Ligand unit (i.e., a targeting agent), D is a Drug Linker unit of formula II:
 
                     
wherein p is an integer of from 1 to 20.
 
 The Ligand unit, described more fully below, is a targeting agent that binds to a target moiety. The Ligand unit can, for example, specifically bind to a cell component (a Cell Binding Agent) or to other target molecules of interest. The Ligand unit can be, for example, a protein, polypeptide or peptide, such as an antibody, an antigen-binding fragment of an antibody, or other binding agent, such as an Fc fusion protein. 
 A second aspect of the present invention provides a compound of formula III: 
 
 
 
 
   
   
 
 
 
 A third aspect of the present invention provides the use of a conjugate of the first aspect of the invention in the manufacture of a medicament for treating a proliferative disease. The third aspect also provides a conjugate of the first aspect of the invention for use in the treatment of a proliferative disease. The third aspect also provides a method of treating a proliferative disease comprising administering a therapeutically effective amount of a conjugate of the first aspect of the invention to a patient in need thereof. 
 One of ordinary skill in the art is readily able to determine whether or not a candidate conjugate treats a proliferative condition for any particular cell type. For example, assays which may conveniently be used to assess the activity offered by a particular compound are described in the examples below. 
 A fourth aspect of the present invention provides the synthesis of a conjugate of the first aspect of the invention comprising conjugating a compound (drug linker) of the second aspect of the invention with a Ligand Unit. 
 
 BRIEF DESCRIPTION OF FIGURES 
   FIG. 1  shows the effect on volume of a NCI-N87 tumour following treatment with a conjugate of the present invention; 
   FIG. 2  shows the effect on volume of a JIMT-1 tumour following treatment with a conjugate of the present invention; 
   FIG. 3  shows the effect on volume of a BT474 tumour following treatment with a conjugate of the present invention. 
 
 LIGAND UNIT 
 The Ligand Unit may be of any kind, and include a protein, polypeptide, peptide and a non-peptidic agent that specifically binds to a target molecule. In some embodiments, the Ligand unit may be a protein, polypeptide or peptide. In some embodiments, the Ligand unit may be a cyclic polypeptide. These Ligand units can include antibodies or a fragment of an antibody that contains at least one target molecule-binding site, lymphokines, hormones, growth factors, or any other cell binding molecule or substance that can specifically bind to a target. 
 The terms “specifically binds” and “specific binding” refer to the binding of an antibody or other protein, polypeptide or peptide to a predetermined molecule (e.g., an antigen). Typically, the antibody or other molecule binds with an affinity of at least about 1×10 7  M −1 , and binds to the predetermined molecule with an affinity that is at least two-fold greater than its affinity for binding to a non-specific molecule (e.g., BSA, casein) other than the predetermined molecule or a closely-related molecule. 
 Examples of Ligand units include those agents described for use in WO 2007/085930, which is incorporated herein. 
 In some embodiments, the Ligand unit is a Cell Binding Agent that binds to an extracellular target on a cell. Such a Cell Binding Agent can be a protein, polypeptide, peptide or a non-peptidic agent. In some embodiments, the Cell Binding Agent may be a protein, polypeptide or peptide. In some embodiments, the Cell Binding Agent may be a cyclic polypeptide. The Cell Binding Agent also may be antibody or an antigen-binding fragment of an antibody. Thus, in one embodiment, the present invention provides an antibody-drug conjugate (ADC). 
 Cell Binding Agent 
 A cell binding agent may be of any kind, and include peptides and non-peptides. These can include antibodies or a fragment of an antibody that contains at least one binding site, lymphokines, hormones, hormone mimetics, vitamins, growth factors, nutrient-transport molecules, or any other cell binding molecule or substance. 
 Peptides 
 In one embodiment, the cell binding agent is a linear or cyclic peptide comprising 4-30, preferably 6-20, contiguous amino acid residues. In this embodiment, it is preferred that one cell binding agent is linked to one monomer or dimer pyrrolobenzodiazepine compound. 
 In one embodiment the cell binding agent comprises a peptide that binds integrin α v β 6 . The peptide may be selective for α v β 6  over XYS. 
 In one embodiment the cell binding agent comprises the A20FMDV-Cys polypeptide. The A20FMDV-Cys has the sequence: NAVPNLRGDLQVLAQKVARTC. Alternatively, a variant of the A20FMDV-Cys sequence may be used wherein one, two, three, four, five, six, seven, eight, nine or ten amino acid residues are substituted with another amino acid residue. Furthermore, the polypeptide may have the sequence NAVXXXXXXXXXXXXXXXRTC. 
 Antibodies 
 The term “antibody” herein is used in the broadest sense and specifically covers monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired biological activity (Miller et al (2003)  Jour. of Immunology  170:4854-4861). Antibodies may be murine, human, humanized, chimeric, or derived from other species. An antibody is a protein generated by the immune system that is capable of recognizing and binding to a specific antigen. (Janeway, C., Travers, P., Walport, M., Shlomchik (2001)  Immuno Biology,  5th Ed., Garland Publishing, New York). A target antigen generally has numerous binding sites, also called epitopes, recognized by CDRs on multiple antibodies. Each antibody that specifically binds to a different epitope has a different structure. Thus, one antigen may have more than one corresponding antibody. An antibody includes a full-length immunoglobulin molecule or an immunologically active portion of a full-length immunoglobulin molecule, i.e., a molecule that contains an antigen binding site that immunospecifically binds an antigen of a target of interest or part thereof, such targets including but not limited to, cancer cell or cells that produce autoimmune antibodies associated with an autoimmune disease. The immunoglobulin can be of any type (e.g. IgG, IgE, IgM, IgD, and IgA), class (e.g. IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule. The immunoglobulins can be derived from any species, including human, murine, or rabbit origin. 
 “Antibody fragments” comprise a portion of a full length antibody, generally the antigen binding or variable region thereof. Examples of antibody fragments include Fab, Fab′, F(ab′) 2 , and scFv fragments; diabodies; linear antibodies; fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, CDR (complementary determining region), and epitope-binding fragments of any of the above which immunospecifically bind to cancer cell antigens, viral antigens or microbial antigens, single-chain antibody molecules; and multispecific antibodies formed from antibody fragments. 
 The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e. the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations which include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al (1975)  Nature  256:495, or may be made by recombinant DNA methods (see, U.S. Pat. No. 4,816,567). The monoclonal antibodies may also be isolated from phage antibody libraries using the techniques described in Clackson et al (1991) Nature, 352:624-628; Marks et al (1991) J. Mol. Biol., 222:581-597 or from transgenic mice carrying a fully human immunoglobulin system (Lonberg (2008) Curr. Opinion 20(4):450-459). 
 The monoclonal antibodies herein specifically include “chimeric” antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Pat. No. 4,816,567; and Morrison et al (1984)  Proc. Natl. Acad. Sci . USA, 81:6851-6855). Chimeric antibodies include “primatized” antibodies comprising variable domain antigen-binding sequences derived from a non-human primate (e.g. Old World Monkey or Ape) and human constant region sequences. 
 An “intact antibody” herein is one comprising a VL and VH domains, as well as a light chain constant domain (CL) and heavy chain constant domains, CH1, CH2 and CH3. The constant domains may be native sequence constant domains (e.g. human native sequence constant domains) or amino acid sequence variant thereof. The intact antibody may have one or more “effector functions” which refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody. Examples of antibody effector functions include C1q binding; complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; and down regulation of cell surface receptors such as B cell receptor and BCR. 
 Depending on the amino acid sequence of the constant domain of their heavy chains, intact antibodies can be assigned to different “classes.” There are five major classes of intact antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into “subclasses” (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2. The heavy-chain constant domains that correspond to the different classes of antibodies are called a, 6, E, y, and p, respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known. 
 Humanisation 
 Techniques to reduce the in vivo immunogenicity of a non-human antibody or antibody fragment include those termed “humanisation”. 
 A “humanized antibody” refers to a polypeptide comprising at least a portion of a modified variable region of a human antibody wherein a portion of the variable region, preferably a portion substantially less than the intact human variable domain, has been substituted by the corresponding sequence from a non-human species and wherein the modified variable region is linked to at least another part of another protein, preferably the constant region of a human antibody. The expression “humanized antibodies” includes human antibodies in which one or more complementarity determining region (“CDR”) amino acid residues and/or one or more framework region (“FW” or “FR”) amino acid residues are substituted by amino acid residues from analogous sites in rodent or other non-human antibodies. The expression “humanized antibody” also includes an immunoglobulin amino acid sequence variant or fragment thereof that comprises an FR having substantially the amino acid sequence of a human immunoglobulin and a CDR having substantially the amino acid sequence of a non-human immunoglobulin. 
 “Humanized” forms of non-human (e.g., murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. Or, looked at another way, a humanized antibody is a human antibody that also contains selected sequences from non-human (e.g. murine) antibodies in place of the human sequences. A humanized antibody can include conservative amino acid substitutions or non-natural residues from the same or different species that do not significantly alter its binding and/or biologic activity. Such antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulins. 
 There are a range of humanisation techniques, including ‘CDR grafting’, ‘guided selection’, ‘deimmunization’, ‘resurfacing’ (also known as ‘veneering’), ‘composite antibodies’, ‘Human String Content Optimisation’ and framework shuffling. 
 CDR Grafting 
 In this technique, the humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary-determining region (CDR) of the recipient antibody are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, camel, bovine, goat, or rabbit having the desired properties (in effect, the non-human CDRs are ‘grafted’ onto the human framework). In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues (this may happen when, for example, a particular FR residue has significant effect on antigen binding). 
 Furthermore, humanized antibodies can comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and maximize antibody performance. Thus, in general, a humanized antibody will comprise all of at least one, and in one aspect two, variable domains, in which all or all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), or that of a human immunoglobulin. 
 Guided Selection 
 The method consists of combining the V H  or V L  domain of a given non-human antibody specific for a particular epitope with a human V H  or V L  library and specific human V domains are selected against the antigen of interest. This selected human VH is then combined with a VL library to generate a completely human VH×VL combination. The method is described in Nature Biotechnology (N.Y.) 12, (1994) 899-903. 
 Composite Antibodies 
 In this method, two or more segments of amino acid sequence from a human antibody are combined within the final antibody molecule. They are constructed by combining multiple human VH and VL sequence segments in combinations which limit or avoid human T cell epitopes in the final composite antibody V regions. Where required, T cell epitopes are limited or avoided by, exchanging V region segments contributing to or encoding a T cell epitope with alternative segments which avoid T cell epitopes. This method is described in US 2008/0206239 A1. 
 Deimmunization 
 This method involves the removal of human (or other second species) T-cell epitopes from the V regions of the therapeutic antibody (or other molecule). The therapeutic antibodies V-region sequence is analysed for the presence of MHC class II-binding motifs by, for example, comparison with databases of MHC-binding motifs (such as the “motifs” database hosted at www.wehi.edu.au). Alternatively, MHC class II-binding motifs may be identified using computational threading methods such as those devised by Altuvia et al. (J. Mol. Biol. 249 244-250 (1995)); in these methods, consecutive overlapping peptides from the V-region sequences are testing for their binding energies to MHC class II proteins. This data can then be combined with information on other sequence features which relate to successfully presented peptides, such as amphipathicity, Rothbard motifs, and cleavage sites for cathepsin B and other processing enzymes. 
 Once potential second species (e.g. human) T-cell epitopes have been identified, they are eliminated by the alteration of one or more amino acids. The modified amino acids are usually within the T-cell epitope itself, but may also be adjacent to the epitope in terms of the primary or secondary structure of the protein (and therefore, may not be adjacent in the primary structure). Most typically, the alteration is by way of substitution but, in some circumstances amino acid addition or deletion will be more appropriate. 
 All alterations can be accomplished by recombinant DNA technology, so that the final molecule may be prepared by expression from a recombinant host using well established methods such as Site Directed Mutagenesis. However, the use of protein chemistry or any other means of molecular alteration is also possible. 
 Resurfacing 
 This method involves:
         (a) determining the conformational structure of the variable region of the non-human (e.g. rodent) antibody (or fragment thereof) by constructing a three-dimensional model of the non-human antibody variable region;   (b) generating sequence alignments using relative accessibility distributions from x-ray crystallographic structures of a sufficient number of non-human and human antibody variable region heavy and light chains to give a set of heavy and light chain framework positions wherein the alignment positions are identical in 98% of the sufficient number of non-human antibody heavy and light chains;   (c) defining for the non-human antibody to be humanized, a set of heavy and light chain surface exposed amino acid residues using the set of framework positions generated in step (b);   (d) identifying from human antibody amino acid sequences a set of heavy and light chain surface exposed amino acid residues that is most closely identical to the set of surface exposed amino acid residues defined in step (c), wherein the heavy and light chain from the human antibody are or are not naturally paired;   (e) substituting, in the amino acid sequence of the non-human antibody to be humanized, the set of heavy and light chain surface exposed amino acid residues defined in step (c) with the set of heavy and light chain surface exposed amino acid residues identified in step (d);   (f) constructing a three-dimensional model of the variable region of the non-human antibody resulting from the substituting specified in step (e);   (g) identifying, by comparing the three-dimensional models constructed in steps (a) and (f), any amino acid residues from the sets identified in steps (c) or (d), that are within 5 Angstroms of any atom of any residue of the complementarity determining regions of the non-human antibody to be humanized; and   (h) changing any residues identified in step (g) from the human to the original non-human amino acid residue to thereby define a non-human antibody humanizing set of surface exposed amino acid residues; with the proviso that step (a) need not be conducted first, but must be conducted prior to step (g).
 
Superhumanization
       
 The method compares the non-human sequence with the functional human germline gene repertoire. Those human genes encoding canonical structures identical or closely related to the non-human sequences are selected. Those selected human genes with highest homology within the CDRs are chosen as FR donors. Finally, the non-human CDRs are grafted onto these human FRs. This method is described in patent WO 2005/079479 A2. 
 Human String Content Optimization 
 This method compares the non-human (e.g. mouse) sequence with the repertoire of human germline genes and the differences are scored as Human String Content (HSC) that quantifies a sequence at the level of potential MHC/T-cell epitopes. The target sequence is then humanized by maximizing its HSC rather than using a global identity measure to generate multiple diverse humanized variants (described in Molecular Immunology, 44, (2007) 1986-1998). 
 Framework Shuffling 
 The CDRs of the non-human antibody are fused in-frame to cDNA pools encompassing all known heavy and light chain human germline gene frameworks. Humanised antibodies are then selected by e.g. panning of the phage displayed antibody library. This is described in    Methods   36, 43-60 (2005). 
 Examples of cell binding agents include those agents described for use in WO 2007/085930, which is incorporated herein. 
 Tumour-associate antigens and cognate antibodies for use in embodiments of the present invention are listed below. 
 Tumor-Associated Antigens and Cognate Antibodies 
 (1) BMPR1B (Bone Morphogenetic Protein Receptor-Type IB) 
 Nucleotide 
 Genbank accession no. NM_001203 
 Genbank version no. NM_001203.2 GI:169790809 
 Genbank record update date: Sep. 23, 2012 02:06 PM 
 Polypeptide 
 Genbank accession no. NP_001194 
 Genbank version no. NP_001194.1 GI:4502431 
 Genbank record update date: Sep. 23, 2012 02:06 PM 
 Cross-References 
 ten Dijke, P., et al Science 264 (5155): 101-104 (1994), Oncogene 14 (11):1377-1382 (1997)); WO2004/063362 (Claim 2); WO2003/042661 (Claim 12); US2003/134790-A1 (Page 38-39); WO2002/102235 (Claim 13; Page 296); WO2003/055443 
 (Page 91-92); WO2002/99122 (Example 2; Page 528-530); WO2003/029421 (Claim 6); WO2003/024392 (Claim 2; FIG. 112); WO2002/98358 (Claim 1; Page 183); WO2002/54940 (Page 100-101); WO2002/59377 (Page 349-350); WO2002/30268 ( Claim  27; Page 376); 15 WO2001/48204 (Example; FIG. 4); NP_001194 bone morphogenetic protein receptor, type IB/pid=NP_001194.1; MIM:603248; AY065994
 
(2) E16 (LAT1, SLC7A5)
 
Nucleotide
 
Genbank accession no. NM_003486
 
Genbank version no. NM_003486.5 GI:71979931
 
Genbank record update date: Jun. 27, 2012 12:06 PM
 
Polypeptide
 
Genbank accession no. NP_003477
 
Genbank version no. NP_003477.4 GI:71979932
 
Genbank record update date: Jun. 27, 2012 12:06 PM
 
Cross References
 
 Biochem. Biophys. Res. Commun.  255 (2), 283-288 (1999),  Nature  395 (6699):288-291 (1998), Gaugitsch, H. W., et 20 al (1992)  J. Biol. Chem.  267 (16):11267-11273); WO2004/048938 (Example 2); WO2004/032842 (Example IV); WO2003/042661 (Claim 12); WO2003/016475 (Claim 1); WO2002/78524 (Example 2); WO2002/99074 (Claim 19; Page 127-129); WO2002/86443 ( Claim  27; Pages 222, 393); WO2003/003906 (Claim 10; Page 293); WO2002/64798 ( Claim  33; Page 93-95); WO2000/14228 (Claim 5; Page 133-136); US2003/224454 (FIG. 3); 25 WO2003/025138 ( Claim  12; Page 150); NP_003477 solute carrier family 7 (cationic amino acid transporter, y+system), member 5/pid=NP_003477.3 —Homo sapiens ; MIM:600182; NM_015923.
 
(3) STEAP1 (Six Transmembrane Epithelial Antigen of Prostate)
 
Nucleotide
 
Genbank accession no. NM_012449
 
Genbank version no. NM_012449.2 GI:22027487
 
Genbank record update date: Sep. 9, 2012 02:57 PM
 
Polypeptide
 
Genbank accession no. NP_036581
 
Genbank version no. NP_036581.1 GI:9558759
 
Genbank record update date: Sep. 9, 2012 02:57 PM
 
Cross References
 
 Cancer Res.  61 (15), 5857-5860 (2001), Hubert, R. S., et al (1999)  Proc. Natl. Acad. Sci. U.S.A.  96 (25):14523-14528); WO2004/065577 (Claim 6); WO2004/027049 (FIG. 1L); EP1394274 (Example 11); WO2004/016225 (Claim 2); WO2003/042661 (Claim 12); US2003/157089 (Example 5); US2003/185830 (Example 5); US2003/064397 (FIG. 2); WO2002/89747 (Example 5; Page 618-619); WO2003/022995 (Example 9; FIG. 13A, 35 Example 53; Page 173, Example 2; FIG. 2A); six transmembrane epithelial antigen of the prostate; MIM:604415.
 
(4) 0772P (CA125, MUC16)
 
Nucleotide
 
Genbank accession no. AF361486
 
Genbank version no. AF361486.3 GI:34501466
 
Genbank record update date: Mar. 11, 2010 07:56 AM
 
Polypeptide
 
Genbank accession no. AAK74120
 
Genbank version no. AAK74120.3 GI:34501467
 
Genbank record update date: Mar. 11, 2010 07:56 AM
 
Cross References
 
 J. Biol. Chem.  276 (29):27371-27375 (2001)); WO2004/045553 (Claim 14); WO2002/92836 ( Claim  6; FIG. 12); WO2002/83866 ( Claim  15; Page 116-121); US2003/124140 (Example 16); GI:34501467;
 
(5) MPF (MPF, MSLN, SMR, Megakaryocyte Potentiating Factor, Mesothelin)
 
Nucleotide
 
Genbank accession no. NM_005823
 
Genbank version no. NM_005823.5 GI:293651528
 
Genbank record update date: Sep. 2, 2012 01:47 PM
 
Polypeptide
 
Genbank accession no. NP_005814
 
Genbank version no. NP_005814.2 GI:53988378
 
Genbank record update date: Sep. 2, 2012 01:47 PM
 
Cross References
 
Yamaguchi, N., et al  Biol. Chem.  269 (2), 805-808 (1994),  Proc. Natl. Acad. Sci. U.S.A.  96 (20):11531-11536 (1999),  Proc. Natl. Acad. Sci. U.S.A.  93 (1):136-140 (1996),  J. Biol. Chem.  270 (37):21984-21990 (1995)); WO2003/101283 (Claim 14); (WO2002/102235 (Claim 13; Page 287-288); WO2002/101075 ( Claim  4; Page 308-309); WO2002/71928 (Page 320-321); WO94/10312 (Page 52-57); IM:601051.
 
(6) Napi3b (NAPI-3B, NPTIIb, SLC34A2, Solute Carrier Family 34 (Sodium Phosphate), Member 2, Type II Sodium-Dependent Phosphate Transporter 3b)
 
Nucleotide
 
Genbank accession no. NM_006424
 
Genbank version no. NM_006424.2 GI:110611905
 
Genbank record update date: Jul. 22, 2012 03:39 PM
 
Polypeptide
 
Genbank accession no. NP_006415
 
Genbank version no. NP_006415.2 GI:110611906
 
Genbank record update date: Jul. 22, 2012 03:39 PM
 
Cross References
 
 J. Biol. Chem.  277 (22):19665-19672 (2002),  Genomics  62 (2):281-284 (1999), Feild, J. A., et al (1999)  Biochem. Biophys. Res. Commun.  258 (3):578-582); WO2004/022778 (Claim 2); EP1394274 (Example 11); WO2002/102235 (Claim 13; Page 326); EP0875569 (Claim 1; Page 17-19); WO2001/57188 ( Claim  20; Page 329); WO2004/032842 (Example IV); WO2001/75177 ( Claim  24; Page 139-140); MIM:604217.
 
(7) Sema 5b (FLJ10372, KIAA1445, Mm.42015, SEMA5B, SEMAG, Semaphorin 5b Hlog, 25 Sema Domain, Seven Thrombospondin Repeats (Type 1 and Type 1-Like), Transmembrane Domain™ and Short Cytoplasmic Domain, (Semaphorin) 5B)
 
Nucleotide
 
Genbank accession no. AB040878
 
Genbank version no. AB040878.1 GI:7959148
 
Genbank record update date: Aug. 2, 2006 05:40 PM
 
Polypeptide
 
Genbank accession no. BAA95969
 
Genbank version no. BAA95969.1 GI:7959149
 
Genbank record update date: Aug. 2, 2006 05:40 PM
 
Cross References
 
Nagase T., et al (2000)  DNA Res.  7 (2):143-150); WO2004/000997 (Claim 1); WO2003/003984 (Claim 1); WO2002/06339 (Claim 1; Page 50); WO2001/88133 (Claim 1; Page 41-43, 48-58); WO2003/054152 (Claim 20); WO2003/101400 (Claim 11); Accession: 30 Q9P283; Genew; HGNC:10737
 
(8) PSCA hlg (2700050C12Rik, C530008016Rik, RIKEN cDNA 2700050C12, RIKEN cDNA 2700050C12 gene)
 
Nucleotide
 
Genbank accession no. AY358628
 
Genbank version no. AY358628.1 GI:37182377
 
Genbank record update date: Dec. 1, 2009 04:15 AM
 
Polypeptide
 
Genbank accession no. AAQ88991
 
Genbank version no. AAQ88991.1 GI:37182378
 
Genbank record update date: Dec. 1, 2009 04:15 AM
 
Cross References
 
Ross et al (2002)  Cancer Res.  62:2546-2553; US2003/129192 (Claim 2); US2004/044180 (Claim 12); US2004/044179 (Claim 11); US2003/096961 (Claim 11); US2003/232056 (Example 5); WO2003/105758 16 (Claim 12); US2003/206918 (Example 5); EP1347046 (Claim 1); WO2003/025148 (Claim 20); GI:37182378.
 
(9) ETBR (Endothelin Type B Receptor)
 
Nucleotide
 
Genbank accession no. AY275463
 
Genbank version no. AY275463.1 GI:30526094
 
Genbank record update date: Mar. 11, 2010 02:26 AM
 
Polypeptide
 
Genbank accession no. AAP32295
 
Genbank version no. AAP32295.1 GI:30526095
 
Genbank record update date: Mar. 11, 2010 02:26 AM
 
Cross References
 
Nakamuta M., et al  Biochem. Biophys. Res. Commun.  177, 34-39, 1991; Ogawa Y., et al  Biochem. Biophys. Res. Commun.  178, 248-255, 1991; Arai H., et al  Jpn. Circ. J.  56, 1303-1307, 1992; Arai H., et al  J. Biol. Chem.  268, 3463-3470, 1993; Sakamoto A., Yanagisawa M., et al  Biochem. Biophys. Res. Commun.  178, 656-663, 1991; Elshourbagy N. A., et al  J. Biol. Chem.  268, 3873-3879, 1993; Haendler B., et al  J. Cardiovasc. Pharmacol.  20, s1-S4, 1992; Tsutsumi M., et al  Gene  228, 43-49, 1999; Strausberg R. L., et al  Proc. Natl. Acad. Sci. U.S.A.  99, 16899-16903, 2002; Bourgeois C., et al  J. Clin. Endocrinol. Metab.  82, 3116-3123, 1997; Okamoto Y., et al  Biol. Chem.  272, 21589-21596, 1997; Verheij J. B., et al  Am. J. Med. Genet.  108, 223-225, 2002; Hofstra R. M. W., et al  Eur. J. Hum. Genet.  5, 180-185, 1997; Puffenberger E. G., et al  Cell  79, 1257-1266, 1994; Attie T., et al,  Hum. Mol. Genet.  4, 2407-2409, 1995; Auricchio A., et al  Hum. Mol. Genet.  5:351-354, 1996; Amiel J., et al  Hum. Mol. Genet.  5, 355-357, 1996; Hofstra R. M. W., et al  Nat. Genet.  12, 445-447, 1996; Svensson P. J., et al  Hum. Genet.  103, 145-148, 1998; Fuchs S., et al  Mol. Med.  7, 115-124, 2001; Pingault V., et al (2002)  Hum. Genet.  111, 198-206; WO2004/045516 (Claim 1); WO2004/048938 (Example 2); WO2004/040000 (Claim 151); WO2003/087768 (Claim 1); 20 WO2003/016475 (Claim 1); WO2003/016475 (Claim 1); WO2002/61087 (FIG. 1); WO2003/016494 (FIG. 6); WO2003/025138 ( Claim  12; Page 144); WO2001/98351 (Claim 1; Page 124-125); EP0522868 ( Claim  8; FIG. 2); WO2001/77172 (Claim 1; Page 297-299); US2003/109676; U.S. Pat. No. 6,518,404 (FIG. 3); U.S. Pat. No. 5,773,223 (Claim 1a; Col 31-34); WO2004/001004.
 
(10) MSG783 (RNF124, Hypothetical Protein FLJ20315)
 
Nucleotide
 
Genbank accession no. NM_017763
 
Genbank version no. NM_017763.4 GI:167830482
 
Genbank record update date: Jul. 22, 2012 12:34 AM
 
Polypeptide
 
Genbank accession no. NP_060233
 
Genbank version no. NP_060233.3 GI:56711322
 
Genbank record update date: Jul. 22, 2012 12:34 AM
 
Cross References
 
WO2003/104275 (Claim 1); WO2004/046342 (Example 2); WO2003/042661 (Claim 12); WO2003/083074 (Claim 14; Page 61); WO2003/018621 (Claim 1); WO2003/024392 (Claim 2; FIG. 93); WO2001/66689 (Example 6); LocusID:54894.
 
(11) STEAP2 (HGNC_8639, IPCA-1, PCANAP1, STAMP1, STEAP2, STMP, Prostate Cancer Associated Gene 1, Prostate Cancer Associated Protein 1, Six Transmembrane Epithelial Antigen of Prostate 2, Six Transmembrane Prostate Protein)
 
Nucleotide
 
Genbank accession no. AF455138
 
Genbank version no. AF455138.1 GI:22655487
 
Genbank record update date: Mar. 11, 2010 01:54 AM
 
Polypeptide
 
Genbank accession no. AAN04080
 
Genbank version no. AAN04080.1 GI:22655488
 
Genbank record update date: Mar. 11, 2010 01:54 AM
 
Cross References
 
Lab. Invest. 82 (11):1573-1582 (2002)); WO2003/087306; US2003/064397 (Claim 1; FIG. 1); WO2002/72596 (Claim 13; Page 54-55); WO2001/72962 (Claim 1; FIG. 4B); WO2003/104270 (Claim 11); WO2003/104270 (Claim 16); US2004/005598 (Claim 22); WO2003/042661 (Claim 12); US2003/060612 ( Claim  12; FIG. 10); WO2002/26822 (Claim 23; FIG. 2); WO2002/16429 ( Claim  12; FIG. 10); GI:22655488.
 
(12) TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, Transient Receptor Potential Cation 5 Channel, Subfamily M, Member 4)
 
Nucleotide
 
Genbank accession no. NM_017636
 
Genbank version no. NM_017636.3 GI:304766649
 
Genbank record update date: Jun. 29, 2012 11:27 AM
 
Polypeptide
 
Genbank accession no. NP_060106
 
Genbank version no. NP_060106.2 GI:21314671
 
Genbank record update date: Jun. 29, 2012 11:27 AM
 
Cross References
 
Xu, X. Z., et al  Proc. Natl. Acad. Sci. U.S.A.  98 (19):10692-10697 (2001),  Cell  109 (3):397-407 (2002),  J. Biol. Chem.  278 (33):30813-30820 (2003)); US2003/143557 (Claim 4); WO2000/40614 (Claim 14; Page 100-103); WO2002/10382 (Claim 1; FIG. 9A); WO2003/042661 (Claim 12); WO2002/30268 ( Claim  27; Page 391); US2003/219806 (Claim 4); WO2001/62794 (Claim 14; FIG. 1A-D); MIM:606936.
 
(13) CRIPTO (CR, CR1, CRGF, CRIPTO, TDGF1, Teratocarcinoma-Derived Growth Factor)
 
Nucleotide
 
Genbank accession no. NM_003212
 
Genbank version no. NM_003212.3 GI:292494881
 
Genbank record update date: Sep. 23, 2012 02:27 PM
 
Polypeptide
 
Genbank accession no. NP_003203
 
Genbank version no. NP_003203.1 GI:4507425
 
Genbank record update date: Sep. 23, 2012 02:27 PM
 
Cross References
 
Ciccodicola, A., et al  EMBO J.  8 (7):1987-1991 (1989),  Am. J. Hum. Genet.  49 (3):555-565 (1991)); US2003/224411 (Claim 1); WO2003/083041 (Example 1); WO2003/034984 (Claim 12); WO2002/88170 (Claim 2; Page 52-53); WO2003/024392 (Claim 2; FIG. 58); WO2002/16413 (Claim 1; Page 94-95, 105); WO2002/22808 (Claim 2; FIG. 1); U.S. Pat. No. 5,854,399 (Example 2; Col 17-18); U.S. Pat. No. 5,792,616 (FIG. 2); MIM:187395.
 
(14) CD21 (CR2 (Complement Receptor 2) or C3DR (C3d/Epstein Barr Virus Receptor) or Hs. 73792)
 
Nucleotide
 
Genbank accession no M26004
 
Genbank version no. M26004.1 GI:181939
 
Genbank record update date: Jun. 23, 2010 08:47 AM
 
Polypeptide
 
Genbank accession no. AAA35786
 
Genbank version no. AAA35786.1 GI:181940
 
Genbank record update date: Jun. 23, 2010 08:47 AM
 
Cross References
 
Fujisaku et al (1989)  J. Biol. Chem.  264 (4):2118-2125); Weis J. J., et al  J. Exp. Med.  167, 1047-1066, 1988; Moore M., et al  Proc. Natl. Acad. Sci. U.S.A.  84, 9194-9198, 1987; Barel M., et al  Mol. Immunol.  35, 1025-1031, 1998; Weis J. J., et al  Proc. Natl. Acad. Sci. U.S.A.  83, 5639-5643, 1986; Sinha S. K., et al (1993)  J. Immunol.  150, 5311-5320; WO2004/045520 (Example 4); US2004/005538 (Example 1); WO2003/062401 (Claim 9); WO2004/045520 (Example 4); WO91/02536 (FIGS. 9.1-9.9); WO2004/020595 (Claim 1); Accession: P20023; Q13866; Q14212; EMBL; M26004; AAA35786.1.
 
(15) CD79b (CD79B, CD793, IGb (Immunoglobulin-Associated Beta), B29)
 
Nucleotide
 
Genbank accession no NM_000626
 
Genbank version no. NM_000626.2 GI:90193589
 
Genbank record update date: Jun. 26, 2012 01:53 PM
 
Polypeptide
 
Genbank accession no. NP_000617
 
Genbank version no. NP_000617.1 GI:11038674
 
Genbank record update date: Jun. 26, 2012 01:53 PM
 
Cross References
 
 Proc. Natl. Acad. Sci. U.S.A . (2003) 100 (7):4126-4131 , Blood  (2002) 100 (9):3068-3076, Muller et al (1992)  Eur. J. Immunol.  22 (6):1621-1625); WO2004/016225 (claim 2, FIG. 140); WO2003/087768, US2004/101874 (claim 1, page 102); WO2003/062401 (claim 9); WO2002/78524 (Example 2); US2002/150573 (claim
 
35 5, page 15); U.S. Pat. No. 5,644,033; WO2003/048202 (claim 1, pages 306 and 309); WO 99/58658,
 
U.S. Pat. No. 6,534,482 (claim 13, FIG. 17A/B); WO2000/55351 (claim 11, pages 1145-1146); MIM:147245
 
(16) FcRH2 (IFGP4, IRTA4, SPAP1A (SH2 Domain Containing Phosphatase Anchor Protein 5 1a), SPAP1B, SPAP1C)
 
Nucleotide
 
Genbank accession no NM_030764
 
Genbank version no. NM_030764.3 GI:227430280
 
Genbank record update date: Jun. 30, 2012 12:30 AM
 
Polypeptide
 
Genbank accession no. NP_110391
 
Genbank version no. NP_110391.2 GI:19923629
 
Genbank record update date: Jun. 30, 2012 12:30 AM
 
Cross References
 
AY358130);  Genome Res.  13 (10):2265-2270 (2003),  Immunogenetics  54 (2):87-95 (2002),  Blood  99 (8):2662-2669 (2002),  Proc. Natl. Acad. Sci. U.S.A.  98 (17):9772-9777 (2001), Xu, M. J., et al (2001)  Biochem. Biophys. Res. Commun.  280 (3):768-775; WO2004/016225 (Claim 2); WO2003/077836; WO2001/38490 (Claim 5; FIG. 18D-1-18D-2); WO2003/097803 (Claim 12); 10 WO2003/089624 (Claim 25); MIM:606509.
 
(17) HER2 (ErbB2)
 
Nucleotide
 
Genbank accession no M11730
 
Genbank version no. M11730.1 GI:183986
 
Genbank record update date: Jun. 23, 2010 08:47 AM
 
Polypeptide
 
Genbank accession no. AAA75493
 
Genbank version no. AAA75493.1 GI:306840
 
Genbank record update date: Jun. 23, 2010 08:47 AM
 
Cross References
 
Coussens L., et al  Science  (1985) 230(4730):1132-1139); Yamamoto T., et al  Nature  319, 230-234, 1986; Semba K., et al  Proc. Natl. Acad. Sci. U.S.A.  82, 6497-6501, 1985; Swiercz J. M., et al  J. Cell Biol.  165, 869-880, 2004; Kuhns J. J., et al  J. Biol. Chem.  274, 36422-36427, 1999; Cho H.-S., et al  Nature  421, 756-760, 2003; Ehsani A., et al (1993)    Genomics   15, 426-429; WO2004/048938 (Example 2); WO2004/027049 (FIG. 11); WO2004/009622; WO2003/081210;
 
WO2003/089904 (Claim 9); WO2003/016475 (Claim 1); US2003/118592; WO2003/008537 (Claim 1); WO2003/055439 (Claim 29; FIG. 1A-B); WO2003/025228 (Claim 37; FIG. 5C); 20 WO2002/22636 (Example 13; Page 95-107); WO2002/12341 ( Claim  68; FIG. 7); WO2002/13847 (Page 71-74); WO2002/14503 (Page 114-117); WO2001/53463 (Claim 2; Page 41-46); WO2001/41787 (Page 15); WO2000/44899 ( Claim  52; FIG. 7); WO2000/20579
 
( Claim  3; FIG. 2); U.S. Pat. No. 5,869,445 ( Claim  3; Col 31-38); WO9630514 (Claim 2; Page 56-61); EP1439393 (Claim 7); WO2004/043361 (Claim 7); WO2004/022709; WO2001/00244 25 (Example 3; FIG. 4); Accession: P04626; EMBL; M11767; AAA35808.1. EMBL; M11761; AAA35808.1
 
Antibodies
 
Abbott: US20110177095
         For example, an antibody comprising CDRs having overall at least 80% sequence identity to CDRs having amino acid sequences of SEQ ID NO:3 (CDR-H1), SEQ ID NO:4 (CDR-H2), SEQ ID NO:5 (CDR-H3), SEQ ID NO:104 and/or SEQ ID NO:6 (CDR-L1), SEQ ID NO:7 (CDR-L2), and SEQ ID NO:8 (CDR-L3), wherein the anti-HER2 antibody or anti-HER2 binding fragment has reduced immunogenicity as compared to an antibody having a VH of SEQ ID NO:1 and a VL of SEQ ID NO:2.
 
Biogen: US20100119511
   For example, ATCC accession numbers: PTA-10355, PTA-10356, PTA-10357, PTA-10358   For example, a purified antibody molecule that binds to HER2 comprising a all six CDR's from an antibody selected from the group consisting of BIIB71F10 (SEQ ID NOs:11, 13), B11B69A09 (SEQ ID NOs:15, 17); BIIB67F10 (SEQ ID NOs:19, 21); BIIB67F11 (SEQ ID NOs:23, 25), BIIB66A12 (SEQ ID NOs:27, 29), BIIB66C01 (SEQ ID NOs:31, 33), BIIB65C10 (SEQ ID NOs:35, 37), BIIB65H09 (SEQ ID NOs:39, 41) and B11B65B03 (SEQ ID NOs:43, 45), or CDRs which are identical or which have no more than two alterations from said CDRs.
 
Herceptin (Genentech)—U.S. Pat. No. 6,054,297; ATCC accession no. CRL-10463 (Genentech)
 
Pertuzumab (Genentech)
   US20110117097
           for example, see SEQ IDs No. 15&16, SEQ IDs No. 17&18, SEQ IDs No. 23&24 & ATCC accession numbers HB-12215, HB-12216, CRL 10463, HB-12697.   
   US20090285837   US20090202546
           for example, ATCC accession numbers: HB-12215, HB-12216, CRL 10463, HB-12698.   
   US20060088523
           for example, ATCC accession numbers: HB-12215, HB-12216   for example, an antibody comprising the variable light and variable heavy amino acid sequences in SEQ ID Nos. 3 and 4, respectively.   for example, an antibody comprising a light chain amino acid sequence selected from SEQ ID No. 15 and 23, and a heavy chain amino acid sequence selected from SEQ ID No. 16 and 24 US20060018899   for example, ATCC accession numbers: (7C2) HB-12215, (7F3) HB-12216, (4D5) CRL-10463, (2C4) HB-12697.   for example, an antibody comprising the amino acid sequence in SEQ ID No. 23, or a deamidated and/or oxidized variant thereof.   
   US2011/0159014
           for example, an antibody having a light chain variable domain comprising the hypervariable regions of SEQ ID NO: 1”.   For example, an antibody having a heavy chain variable domain comprising the hypervariable regions of SEQ ID NO: 2.   
   US20090187007
 
Glycotope: TrasGEX antibody http://www.glycotope.com/pipeline
   For example, see International Joint Cancer Institute and Changhai Hospital Cancer Cent: HMTI-Fc Ab—Gao J., et al  BMB Rep.  2009 Oct. 31; 42(10):636-41.
 
Symphogen: US20110217305
 
Union Stem Cell &Gene Engineering, China—Liu HQ., et al  Xi Bao Yu Fen Zi Mian YiXue Za Zhi.  2010 May; 26(5):456-8.
 
(18) NCA (CEACAM6)
 
Nucleotide
 
Genbank accession no M18728
 
Genbank version no. M18728.1 GI:189084
 
Genbank record update date: Jun. 23, 2010 08:48 AM
 
Polypeptide
 
Genbank accession no. AAA59907
 
Genbank version no. AAA59907.1 GI:189085
 
Genbank record update date: Jun. 23, 2010 08:48 AM
 
Cross References
 
Barnett T., et al    Genomics   3, 59-66, 1988; Tawaragi Y., et al  Biochem. Biophys. Res. Commun.  150, 89-96, 1988; Strausberg R. L., et al  Proc. Natl. Acad. Sci. U.S.A.  99:16899-16903, 2002; WO2004/063709; EP1439393 (Claim 7); WO2004/044178 (Example 4); WO2004/031238; WO2003/042661 (Claim 12); WO2002/78524 (Example 2); WO2002/86443 ( Claim  27; Page 427); WO2002/60317 (Claim 2); Accession: P40199; Q14920; EMBL; M29541; AAA59915.1. EMBL; M18728.
 
(19) MDP (DPEP1)
 
Nucleotide
 
Genbank accession no BC017023
 
Genbank version no. BC017023.1 GI:16877538
 
Genbank record update date: Mar. 6, 2012 01:00 PM
 
Polypeptide
 
Genbank accession no. AAH17023
 
Genbank version no. AAH17023.1 GI:16877539
 
Genbank record update date: Mar. 6, 2012 01:00 PM
 
Cross References
 
 Proc. Natl. Acad. Sci. U.S.A.  99 (26):16899-16903 (2002)); WO2003/016475 (Claim 1); WO2002/64798 ( Claim  33; Page 85-87); JP05003790 (FIG. 6-8); WO99/46284 (FIG. 9); MIM:179780.
 
(20) IL20R-Alpha (IL20Ra, ZCYTOR7)
 
Nucleotide
 
Genbank accession no AF184971
 
Genbank version no. AF184971.1 GI:6013324
 
Genbank record update date: Mar. 10, 2010 10:00 PM
 
Polypeptide
 
Genbank accession no. AAF01320
 
Genbank version no. AAF01320.1 GI:6013325
 
Genbank record update date: Mar. 10, 2010 10:00 PM
 
Cross References
 
Clark H. F., et al  Genome Res.  13, 2265-2270, 2003; Mungall A. J., et al  Nature  425, 805-811, 2003; Blumberg H., et al  Cell  104, 9-19, 2001; Dumoutier L., et al  J. Immunol.  167, 3545-3549,
 
2001; Parrish-Novak J., et al  J. Biol. Chem.  277, 47517-47523, 2002; Pletnev S., et al (2003)
 
10  Biochemistry  42:12617-12624; Sheikh F., et al (2004)  J. Immunol.  172, 2006-2010; EP1394274 (Example 11); US2004/005320 (Example 5); WO2003/029262 (Page 74-75); WO2003/002717 (Claim 2; Page 63); WO2002/22153 (Page 45-47); US2002/042366 (Page
 
20-21); WO2001/46261 (Page 57-59); WO2001/46232 (Page 63-65); WO98/37193 (Claim 1;
 
Page 55-59); Accession: Q9UHF4; Q6UWA9; Q96SH8; EMBL; AF184971; AAF01320.1.
 
(21) Brevican (BCAN, BEHAB)
 
Nucleotide
 
Genbank accession no AF229053
 
Genbank version no. AF229053.1 GI:10798902
 
Genbank record update date: Mar. 11, 2010 12:58 AM
 
Polypeptide
 
Genbank accession no. AAG23135
 
Genbank version no. AAG23135.1 GI:10798903
 
Genbank record update date: Mar. 11, 2010 12:58 AM
 
Cross References
 
Gary S. C., et al  Gene  256, 139-147, 2000; Clark H. F., et al  Genome Res.  13, 2265-2270, 2003; Strausberg R. L., et al  Proc. Natl. Acad. Sci. U.S.A.  99, 16899-16903, 2002; US2003/186372 (Claim 11); US2003/186373 (Claim 11); US2003/119131 (Claim 1; FIG. 52); US2003/119122 (Claim 1; FIG. 52); US2003/119126 (Claim 1); US2003/119121 (Claim 1; FIG. 52); US2003/119129 (Claim 1); US2003/119130 (Claim 1); US2003/119128 (Claim 1; FIG. 52); US2003/119125 (Claim 1); WO2003/016475 (Claim 1); WO2002/02634 (Claim 1)
 
(22) EphB2R (DRT, ERK, Hek5, EPHT3, Tyro5)
 
Nucleotide
 
Genbank accession no NM_004442
 
Genbank version no. NM_004442.6 GI:111118979
 
Genbank record update date: Sep. 8, 2012 04:43 PM
 
Polypeptide
 
Genbank accession no. NP_004433
 
Genbank version no. NP_004433.2 GI:21396504
 
Genbank record update date: Sep. 8, 2012 04:43 PM
 
Cross References
 
Chan, J. and Watt, V. M., Oncogene 6 (6), 1057-1061 (1991) Oncogene 10 (5):897-905 (1995), Annu. Rev. Neurosci. 21:309-345 (1998), Int. Rev. Cytol. 196:177-244 (2000)); WO2003042661 (Claim 12); WO200053216 (Claim 1; Page 41); WO2004065576 (Claim 1); WO2004020583 (Claim 9); WO2003004529 (Page 128-132); WO200053216 (Claim 1; Page 42); MIM:600997.
 
(23) ASLG659 (B7h)
 
Nucleotide
 
Genbank accession no. AX092328
 
Genbank version no. AX092328.1 GI:13444478
 
Genbank record update date: Jan. 26, 2011 07:37 AM
 
Cross References
 
US2004/0101899 (Claim 2); WO2003104399 (Claim 11); WO2004000221 (FIG. 3); US2003/165504 (Claim 1); US2003/124140 (Example 2); US2003/065143 (FIG. 60); WO2002/102235 (Claim 13; Page 299); US2003/091580 (Example 2); WO2002/10187 ( Claim  6; FIG. 10); WO2001/94641 ( Claim  12; FIG. 7b); WO2002/02624 (Claim 13; FIG. 1A-1B); US2002/034749 ( Claim  54; Page 45-46); WO2002/06317 (Example 2; Page 320-321, Claim 34; Page 321-322); WO2002/71928 (Page 468-469); WO2002/02587 (Example 1; FIG. 1); WO2001/40269 (Example 3; Pages 190-192); WO2000/36107 (Example 2; Page 205-207); WO2004/053079 (Claim 12); WO2003/004989 (Claim 1); WO2002/71928 (Page 233-234, 452-453); WO 01/16318.
 
(24) PSCA (Prostate Stem Cell Antigen Precursor)
 
Nucleotide
 
Genbank accession no AJ297436
 
Genbank version no. AJ297436.1 GI:9367211
 
Genbank record update date: Feb. 1, 2011 11:25 AM
 
Polypeptide
 
Genbank accession no. CAB97347
 
Genbank version no. CAB97347.1 GI:9367212
 
Genbank record update date: Feb. 1, 2011 11:25 AM
 
Cross References
 
Reiter R. E., et al  Proc. Natl. Acad. Sci. U.S.A.  95, 1735-1740, 1998; Gu Z., et al  Oncogene  19,
 
1288-1296, 2000 ; Biochem. Biophys. Res. Commun . (2000) 275(3):783-788; WO2004/022709; EP1394274 (Example 11); US2004/018553 (Claim 17); WO2003/008537 (Claim 1); WO2002/81646 (Claim 1; Page 164); WO2003/003906 (Claim 10; Page 288); WO2001/40309 (Example 1; FIG. 17); US2001/055751 (Example 1; FIG. 1 b); WO2000/32752 ( Claim  18; FIG. 1); WO98/51805 (Claim 17; Page 97); WO98/51824 (Claim 10; Page 94); WO98/40403 (Claim 2; FIG. 1B); Accession: 043653; EMBL; AF043498; AAC39607.1
 
(25) GEDA
 
Nucleotide
 
Genbank accession no AY260763
 
Genbank version no. AY260763.1 GI:30102448
 
Genbank record update date: Mar. 11, 2010 02:24 AM
 
Polypeptide
 
Genbank accession no. AAP14954
 
Genbank version no. AAP14954.1 GI:30102449
 
Genbank record update date: Mar. 11, 2010 02:24 AM
 
Cross References
 
AP14954 lipoma HMGIC fusion-partnerlike protein/pid=AAP14954.1 —Homo sapiens  (human); WO2003/054152 (Claim 20); WO2003/000842 (Claim 1); WO2003/023013 (Example 3, Claim 20); US2003/194704 (Claim 45); GI:30102449;
 
(26) BAFF-R (B Cell-Activating Factor Receptor,  BLyS Receptor  3, BR3)
 
Nucleotide
 
Genbank accession no AF116456
 
Genbank version no. AF116456.1 GI:4585274
 
Genbank record update date: Mar. 10, 2010 09:44 PM
 
Polypeptide
 
Genbank accession no. AAD25356
 
Genbank version no. AAD25356.1 GI:4585275
 
Genbank record update date: Mar. 10, 2010 09:44 PM
 
Cross References
 
BAFF receptor/pid=NP_443177.1 —Homo sapiens : Thompson, J. S., et al  Science  293 (5537), 2108-2111 (2001); WO2004/058309; WO2004/011611; WO2003/045422 (Example; Page 32-33); WO2003/014294 (Claim 35; FIG. 6B); WO2003/035846 (Claim 70; Page 615-616); WO2002/94852 (Col 136-137); WO2002/38766 ( Claim  3; Page 133); WO2002/24909 (Example 3; FIG. 3); MIM:606269; NP_443177.1; NM_052945_1; AF132600
 
(27) CD22 (B-Cell Receptor CD22-B Isoform, BL-CAM, Lyb-8, Lyb8, SIGLEC-2, FLJ22814)
 
Nucleotide
 
Genbank accession no AK026467
 
Genbank version no. AK026467.1 GI:10439337
 
Genbank record update date: Sep. 11, 2006 11:24 PM
 
Polypeptide
 
Genbank accession no. BAB15489
 
Genbank version no. BAB15489.1 G1:10439338
 
Genbank record update date: Sep. 11, 2006 11:24 PM
 
Cross References
 
Wilson et al (1991)  J. Exp. Med.  173:137-146; WO2003/072036 (Claim 1; FIG. 1); IM:107266; NP_001762.1; NM_001771_1.
 
(27A) Cd22 (Cd22 Molecule)
 
Nucleotide
 
Genbank accession no X52785
 
Genbank version no. X52785.1 G1:29778
 
Genbank record update date: Feb. 2, 2011 10:09 AM
 
Polypeptide
 
Genbank accession no. CAA36988
 
Genbank version no. CAA36988.1 G1:29779
 
Genbank record update date: Feb. 2, 2011 10:09 AM
 
Cross References
 
Stamenkovic I. et al.,  Nature  345 (6270), 74-77 (1990)??
 
Other Information
 
Official Symbol: CD22
 
Other Aliases: SIGLEC-2, SIGLEC2 Other Designations: B-cell receptor CD22; B-lymphocyte cell adhesion molecule; BL-CAM; CD22 antigen; T-cell surface antigen Leu-14; sialic acid binding Ig-like lectin 2; sialic acid-binding Ig-like lectin 2
 
Antibodies
 
G5/44 (Inotuzumab): DiJoseph J F., et al  Cancer Immunol Immunother.  2005 January; 54(1):11-24.
 
Epratuzumab—Goldenberg DM., et al  Expert Rev Anticancer Ther.  6(10): 1341-53, 2006.
 
(28) CD79a (CD79A, CD79alpha), Immunoglobulin-Associated Alpha, a B Cell-Specific Protein that Covalently Interacts with Ig Beta (CD79B) and Forms a Complex on the Surface with Ig M 35 Molecules, Transduces a Signal Involved in B-Cell Differentiation), Pl: 4.84, MW: 25028 Tm: 2 [P] Gene Chromosome: 19q13.2).
 
Nucleotide
 
Genbank accession no NM_001783
 
Genbank version no. NM_001783.3 GI:90193587
 
Genbank record update date: Jun. 26, 2012 01:48 PM
 
Polypeptide
 
Genbank accession no. NP_001774
 
Genbank version no. NP_001774.1 GI:4502685
 
Genbank record update date: Jun. 26, 2012 01:48 PM
 
Cross References
 
WO2003/088808, US2003/0228319; WO2003/062401 (claim 9); US2002/150573 ( claim  4, pages 13-14); WO99/58658 (claim 13, FIG. 16); WO92/07574 (FIG. 1); U.S. Pat. No. 5,644,033; Ha et al (1992)  J. Immunol.  148(5):1526-1531; Müller et al (1992)  Eur. J. Immunol.  22:1621-1625; Hashimoto et al (1994)  Immunogenetics  40(4):287-295; Preud'homme et al (1992) Clin. Exp.
 
5  Immunol.  90(1):141-146; Yu et al (1992)  J. Immunol.  148(2) 633-637; Sakaguchi et al (1988)
 
 EMBO J.  7(11):3457-3464
 
(29) CXCR5 (Burkitt's Lymphoma Receptor 1, a G Protein-Coupled Receptor that is Activated by the CXCL13 Chemokine, Functions in Lymphocyte Migration and Humoral Defense, Plays a
 
10 Role in HIV-2 Infection and Perhaps Development of AIDS, Lymphoma, Myeloma, and Leukemia); 372 Aa, Pl: 8.54 MW: 41959 TM: 7 [P] Gene Chromosome: 11q23.3,
 
Nucleotide
 
Genbank accession no NM_001716
 
Genbank version no. NM_001716.4 GI:342307092
 
Genbank record update date: Sep. 30, 2012 01:49 PM
 
Polypeptide
 
Genbank accession no. NP_001707
 
Genbank version no. NP_001707.1 GI:4502415
 
Genbank record update date: Sep. 30, 2012 01:49 PM
 
Cross References
 
WO2004/040000; WO2004/015426; US2003/105292 (Example 2); U.S. Pat. No. 6,555,339 (Example 2); WO2002/61087 (FIG. 1); WO2001/57188 ( Claim  20, page 269); WO2001/72830 (pages 12-13); WO2000/22129 (Example 1, pages 152-153, Example 2, pages 254-256); WO99/28468 (claim 1, page 38); U.S. Pat. No. 5,440,021 (Example 2, col 49-52); WO94/28931 (pages 56-58); WO92/17497 (claim 7, FIG. 5); Dobner et al (1992)  Eur. J. Immunol.  22:2795-2799; Barella et al (1995)  Biochem. J.  309:773-779
 
(30) HLA-DOB (Beta Subunit of MHC Class II Molecule (La Antigen) that Binds Peptides and 20 Presents them to CD4+T Lymphocytes); 273 Aa, Pl: 6.56, MW: 30820. TM: 1 [P] Gene Chromosome: 6p21.3)
 
Nucleotide
 
Genbank accession no NM_002120
 
Genbank version no. NM_002120.3 GI:118402587
 
Genbank record update date: Sep. 8, 2012 04:46 PM
 
Polypeptide
 
Genbank accession no. NP_002111
 
Genbank version no. NP_002111.1 GI:4504403
 
Genbank record update date: Sep. 8, 2012 04:46 PM
 
Cross References
 
Tonnelle et al (1985)  EMBO J.  4(11):2839-2847; Jonsson et al (1989)  Immunogenetics  29(6):411-413; Beck et al (1992)  J. Mol. Biol.  228:433-441; Strausberg et al (2002)  Proc. Natl. Acad. Sci USA  99:16899-16903; Servenius et al (1987)  J. Biol. Chem.  262:8759-8766; Beck et al (1996)  J. Mol. Biol.  255:1-13; Naruse et al (2002)  Tissue Antigens  59:512-519; WO99/58658 (claim 13, FIG. 15); U.S. Pat. No. 6,153,408 (Col 35-38); U.S. Pat. No. 5,976,551 (col 168-170); U.S. Pat. No. 6,011,146 (col 145-146); Kasahara et al (1989)  Immunogenetics  30(1):66-68; Larhammar et al (1985)  J. Biol. Chem.  260(26):14111-14119
 
(31) P2X5 (Purinergic Receptor P2X Ligand-Gated Ion Channel 5, an Ion Channel Gated by Extracellular ATP, May be Involved in Synaptic Transmission and Neurogenesis, Deficiency May Contribute to the Pathophysiology of Idiopathic Detrusor Instability); 422 Aa), Pl: 7.63, MW: 47206 TM: 1 [P] Gene Chromosome: 17p13.3).
 
Nucleotide
 
Genbank accession no NM_002561
 
Genbank version no. NM_002561.3 GI:325197202
 
Genbank record update date: Jun. 27, 2012 12:41 AM
 
Polypeptide
 
Genbank accession no. NP_002552
 
Genbank version no. NP_002552.2 GI:28416933
 
Genbank record update date: Jun. 27, 2012 12:41 AM
 
Cross References
 
Le et al (1997)  FEBS Lett.  418(1-2):195-199; WO2004/047749; WO2003/072035 (claim 10); Touchman et al (2000)  Genome Res.  10:165-173; WO2002/22660 (claim 20); WO2003/093444 (claim 1); WO2003/087768 (claim 1); WO2003/029277 (page 82)
 
(32) CD72 (B-Cell Differentiation Antigen CD72, Lyb-2); 359 Aa, Pl: 8.66, MW: 40225, TM: 1 5 [P] Gene Chromosome: 9p13.3).
 
Nucleotide
 
Genbank accession no NM_001782
 
Genbank version no. NM_001782.2 GI:194018444
 
Genbank record update date: Jun. 26, 2012 01:43 PM
 
Polypeptide
 
Genbank accession no. NP_001773
 
Genbank version no. NP_001773.1 GI:4502683
 
Genbank record update date: Jun. 26, 2012 01:43 PM
 
Cross References
 
WO2004042346 (claim 65); WO2003/026493 (pages 51-52, 57-58); WO2000/75655 (pages 105-106); Von Hoegen et al (1990)  J. Immunol.  144(12):4870-4877; Strausberg et al (2002)  Proc. Natl. Acad. Sci USA  99:16899-16903.
 
(33) LY64 (Lymphocyte Antigen 64 (RP105), Type I Membrane Protein of the Leucine Rich Repeat (LRR) Family, Regulates B-Cell Activation and Apoptosis, Loss of Function is Associated with Increased Disease Activity in Patients with Systemic Lupus Erythematosis); 661 Aa, pl: 6.20, MW: 74147 TM: 1 [P] Gene Chromosome: 5q12).
 
Nucleotide
 
Genbank accession no NM_005582
 
Genbank version no. NM_005582.2 GI:167555126
 
Genbank record update date: Sep. 2, 2012 01:50 PM
 
Polypeptide
 
Genbank accession no. NP_005573
 
Genbank version no. NP_005573.2 GI:167555127
 
Genbank record update date: Sep. 2, 2012 01:50 PM
 
Cross References
 
US2002/193567; WO97/07198 (claim 11, pages 39-42); Miura et al (1996)  Genomics  38(3):299-304; Miura et al (1998)  Blood  92:2815-2822; WO2003/083047; WO97/44452 ( claim  8, pages 57-61); WO2000/12130 (pages 24-26).
 
(34) FcRH1 (Fc Receptor-Like Protein 1, a Putative Receptor for the Immunoglobulin Fc Domain that Contains C2 Type Ig-Like and ITAM Domains, May have a Role in B- Lymphocyte  20 Differentiation); 429 Aa, Pl: 5.28, MW: 46925 TM: 1 [P] Gene Chromosome: 1q21-1q22)
 
Nucleotide
 
Genbank accession no NM_052938
 
Genbank version no. NM_052938.4 GI:226958543
 
Genbank record update date: Sep. 2, 2012 01:43 PM
 
Polypeptide
 
Genbank accession no. NP_443170
 
Genbank version no. NP_443170.1 GI:16418419
 
Genbank record update date: Sep. 2, 2012 01:43 PM
 
Cross References
 
WO2003/077836; WO2001/38490 ( claim  6, FIG. 18E-1-18-E-2); Davis et al (2001)  Proc. Natl. Acad. Sci USA  98(17):9772-9777; WO2003/089624 (claim 8); EP1347046 (claim 1); WO2003/089624 (claim 7).
 
(35) IRTA2 (Immunoglobulin Superfamily Receptor Translocation Associated 2, a Putative Immunoreceptor with Possible Roles in B Cell Development and Lymphomagenesis; Deregulation of the Gene by Translocation Occurs in Some B Cell Malignancies); 977 Aa, pl: 6.88, MW: 106468, TM: 1 [P] Gene Chromosome: 1q21)
 
Nucleotide
 
Genbank accession no AF343662
 
Genbank version no. AF343662.1 GI:13591709
 
Genbank record update date: Mar. 11, 2010 01:16 AM
 
Polypeptide
 
Genbank accession no. AAK31325
 
Genbank version no. AAK31325.1 GI:13591710
 
Genbank record update date: Mar. 11, 2010 01:16 AM
 
Cross References
 
AF343663, AF343664, AF343665, AF369794, AF397453, AK090423, AK090475, AL834187, AY358085; Mouse:AK089756, AY158090, AY506558; NP_112571.1; WO2003/024392 (claim 2, FIG. 97); Nakayama et al (2000)  Biochem. Biophys. Res. Commun.  277(1):124-127; WO2003/077836; WO2001/38490 ( claim  3, FIG. 18B-1-18B-2).
 
(36) TENB2 (TMEFF2, Tomoregulin, TPEF, HPP1, TR, Putative Transmembrane 35 Proteoglycan, Related to the EGF/Heregulin Family of Growth Factors and Follistatin); 374 Aa)
 
Nucleotide
 
Genbank accession no AF179274
 
Genbank version no. AF179274.2 GI:12280939
 
Genbank record update date: Mar. 11, 2010 01:05 AM
 
Polypeptide
 
Genbank accession no. AAD55776
 
Genbank version no. AAD55776.2 GI:12280940
 
Genbank record update date: Mar. 11, 2010 01:05 AM
 
Cross References
 
NCBI Accession: AAD55776, AAF91397, AAG49451, NCBI RefSeq: NP_057276; NCBI Gene: 23671; OMIM: 605734; SwissProt Q9UIK5; AY358907, CAF85723, CQ782436; WO2004/074320; JP2004113151; WO2003/042661; WO2003/009814; EP1295944 (pages 69-70); WO2002/30268 (page 329); WO2001/90304; US2004/249130; US2004/022727; WO2004/063355; US2004/197325; US2003/232350; US2004/005563; US2003/124579; Horie et al (2000)  Genomics  67:146-152; Uchida et al (1999)  Biochem. Biophys. Res. Commun.  266:593-602; Liang et al (2000)  Cancer Res.  60:4907-12; Glynne-Jones et al (2001)  Int J Cancer . October 15; 94(2):178-84.
 
(37) PSMA-FOLH1 (Folate Hydrolase (Prostate-Specific Membrane Antigen) 1)
 
Nucleotide
 
Genbank accession no M99487
 
Genbank version no. M99487.1 G1:190663
 
Genbank record update date: Jun. 23, 2010 08:48 AM
 
Polypeptide
 
Genbank accession no. AAA60209
 
Genbank version no. AAA60209.1 GI:190664
 
Genbank record update date: Jun. 23, 2010 08:48 AM
 
Cross References
 
Israeli R. S., et al  Cancer Res.  53 (2), 227-230 (1993)
 
Other Information
 
Official Symbol: FOLH1
 
Other Aliases: GIG27, FGCP, FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA, mGCP
 
Other Designations: N-acetylated alpha-linked acidic dipeptidase 1; N-acetylated-alpha-linked acidic dipeptidase I; NAALADase I; cell growth-inhibiting  gene  27 protein; folylpoly-gamma-glutamate carboxypeptidase; glutamate carboxylase II; glutamate carboxypeptidase 2; glutamate carboxypeptidase II; membrane glutamate carboxypeptidase; prostate specific membrane antigen variant F; pteroylpoly-gamma-glutamate carboxypeptidase
 
Antibodies
 
U.S. Pat. No. 7,666,425:
 
Antibodies produces by Hybridomas having the following ATCC references: ATCC accession No. HB-12101, ATCC accession No. HB-12109, ATCC accession No. HB-12127 and ATCC accession No. HB-12126.
 
Proscan: a monoclonal antibody selected from the group consisting of 8H12, 3E11, 17G1, 29B4, 30C1 and 20F2 (U.S. Pat. No. 7,811,564; Moffett S., et al Hybridoma (Larchmt). 2007 December; 26(6):363-72).
 
Cytogen: monoclonal antibodies 7E11-C5 (ATCC accession No. HB 10494) and 9H10-A4 (ATCC accession No. HB11430)—U.S. Pat. No. 5,763,202
 
GlycoMimetics: NUH2—ATCC accession No. HB 9762 (U.S. Pat. No. 7,135,301)
 
Human Genome Science: HPRAJ70—ATCC accession No. 97131 (U.S. Pat. No. 6,824,993); Amino acid sequence encoded by the cDNA clone (HPRAJ70) deposited as American Type Culture Collection (“ATCC”) Deposit No. 97131
 
Medarex: Anti-PSMA antibodies that lack fucosyl residues—U.S. Pat. No. 7,875,278
 
Mouse anti-PSMA antibodies include the 3F5.4G6, 3D7.1.1, 4E10-1.14, 3E11, 4D8, 3E6, 3C9, 2C7, 1G3, 3C4, 3C6, 4D4, 1G9, 5C8B9, 3G6, 4C8B9, and monoclonal antibodies. Hybridomas secreting 3F5.4G6, 3D7.1.1, 4E10-1.14, 3E11, 4D8, 3E6, 3C9, 2C7, 1G3, 3C4, 3C6, 4D4, 1G9, 5C8B9, 3G6 or 4C8B9 have been publicly deposited and are described in U.S. Pat. No. 6,159,508. Relevant hybridomas have been publicly deposited and are described in U.S. Pat. No. 6,107,090. Moreover, humanized anti-PSMA antibodies, including a humanized version of J591, are described in further detail in PCT Publication WO 02/098897.
 
Other mouse anti-human PSMA antibodies have been described in the art, such as mAb 107-1A4 (Wang, S. et al. (2001) Int. J. Cancer 92:871-876) and mAb 2C9 (Kato, K. et al. (2003) Int. J. Urol. 10:439-444).
 
Examples of human anti-PSMA monoclonal antibodies include the 4A3, 7F12, 8C12, 8A11, 16F9, 2A10, 2C6, 2F5 and 1C3 antibodies, isolated and structurally characterized as originally described in PCT Publications WO 01/09192 and WO 03/064606 and in U.S. Provisional Application Ser. No. 60/654,125, entitled “Human Monoclonal Antibodies to Prostate Specific Membrane Antigen (PSMA)”, filed on Feb. 18, 2005. The V.sub.H amino acid sequences of 4A3, 7F12, 8C12, 8A11, 16F9, 2A10, 2C6, 2F5 and 1C3 are shown in SEQ ID NOs: 1-9, respectively. The V.sub.L amino acid sequences of 4A3, 7F12, 8C12, 8A11, 16F9, 2A10, 2C6, 2F5 and 1C3 are shown in SEQ ID NOs: 10-18, respectively.
 
Other human anti-PSMA antibodies include the antibodies disclosed in PCT Publication WO 03/034903 and US Application No. 2004/0033229.
 
NW Biotherapeutics: A hybridoma cell line selected from the group consisting of 3F5.4G6 having ATCC accession number HB12060, 3D7-1.1. having ATCC accession number HB12309, 4E10-1.14 having ATCC accession number HB12310, 3E11 (ATCC HB12488), 4D8 (ATCC HB12487), 3E6 (ATCC HB12486), 3C9 (ATCC HB12484), 2C7 (ATCC HB12490), 1G3 (ATCC HB12489), 3C4 (ATCC HB12494), 3C6 (ATCC HB12491), 4D4 (ATCC HB12493), 1G9 (ATCC HB12495), 5C8B9 (ATCC HB12492) and 3G6 (ATCC HB12485)—see U.S. Pat. No. 6,150,508
 
PSMA Development Company/Progenics/Cytogen—Seattle Genetics: mAb 3.9, produced by the hybridoma deposited under ATCC Accession No. PTA-3258 or mAb 10.3, produced by the hybridoma deposited under ATCC Accession No. PTA-3347—U.S. Pat. No. 7,850,971
 
PSMA Development Company—Compositions of PSMA antibodies (US 20080286284, Table 1)
   This application is a divisional of U.S. patent application Ser. No. 10/395,894, filed on Mar. 21, 2003 (U.S. Pat. No. 7,850,971)
 
University Hospital Freiburg, Germany— mAbs  3/A12, 3/E7, and 3/F11 (Wolf P., et al  Prostate.  2010 Apr. 1; 70(5):562-9).
 
(38) SST (Somatostatin Receptor; Note that there are 5 Subtypes)
 
(38.1) SSTR2 (Somatostatin Receptor 2)
 
Nucleotide
 
Genbank accession no NM_001050
 
Genbank version no. NM_001050.2 GI:44890054
 
Genbank record update date: Aug. 19, 2012 01:37 PM
 
Polypeptide
 
Genbank accession no. NP_001041
 
Genbank version no. NP_001041.1 GI:4557859
 
Genbank record update date: Aug. 19, 2012 01:37 PM
 
Cross References
 
Yamada Y., et al Proc. Natl. Acad. Sci. U.S.A. 89 (1), 251-255 (1992); Susini C., et al Ann Oncol. 2006 December; 17(12):1733-42
 
Other Information
 
Official Symbol: SSTR2
 
Other Designations: SRIF-1; SS2R; somatostatin receptor type 2
 
(38.2) SSTR5 (Somatostatin Receptor 5)
 
Nucleotide
 
Genbank accession no D16827
 
Genbank version no. D16827.1 GI:487683
 
Genbank record update date: Aug. 1, 2006 12:45 PM
 
Polypeptide
 
Genbank accession no. BAA04107
 
Genbank version no. BAA04107.1 GI:487684
 
Genbank record update date: Aug. 1, 2006 12:45 PM
 
Cross References
 
Yamada, Y., et al  Biochem. Biophys. Res. Commun.  195 (2), 844-852 (1993)
 
Other Information
 
Official Symbol: SSTR5
 
Other Aliases: SS-5-R
 
Other Designations: Somatostatin receptor subtype 5; somatostatin receptor type 5
 
(38.3) SSTR1
 
(38.4) SSTR3
 
(38.5) SSTR4
 
AvB6—Both Subunits (39+40)
 
(39) ITGAV (Integrin, Alpha V;
 
Nucleotide
 
Genbank accession no M14648 J02826 M18365
 
Genbank version no. M14648.1 GI:340306
 
Genbank record update date: Jun. 23, 2010 08:56 AM
 
Polypeptide
 
Genbank accession no. AAA36808
 
Genbank version no. AAA36808.1 GI:340307
 
Genbank record update date: Jun. 23, 2010 08:56 AM
 
Cross References
 
Suzuki S., et al  Proc. Natl. Acad. Sci. U.S.A.  83 (22), 8614-8618 (1986)
 
Other Information
 
Official Symbol: ITGAV
 
Other Aliases: CD51, MSK8, VNRA, VTNR
 
Other Designations: antigen identified by monoclonal antibody L230; integrin alpha-V; integrin alphaVbeta3; integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51); vitronectin receptor subunit alpha
 
(40) ITGB6 (Integrin, Beta 6)
 
Nucleotide
 
Genbank accession no NM_000888
 
Genbank version no. NM_000888.3 GI:9966771
 
Genbank record update date: Jun. 27, 2012 12:46 AM
 
Polypeptide
 
Genbank accession no. NP_000879
 
Genbank version no. NP_000879.2 GI:9625002
 
Genbank record update date: Jun. 27, 2012 12:46 AM
 
Cross References
 
Sheppard D. J., et al  Biol. Chem.  265 (20), 11502-11507 (1990)
 
Other Information
 
Official Symbol: ITGB6
 
Other Designations: integrin beta-6
 
Antibodies
 
Biogen: U.S. Pat. No. 7,943,742—Hybridoma clones 6.3G9 and 6.8G6 were deposited with the ATCC, accession numbers ATCC PTA-3649 and -3645, respectively.
 
Biogen: U.S. Pat. No. 7,465,449—In some embodiments, the antibody comprises the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 6.1A8, 6.3G9, 6.8G6, 6.2B1, 6.2B10, 6.2A1, 6.2E5, 7.1G10, 7.7G5, or 7.1C5.
 
Centocor (J&J): U.S. Pat. Nos. 7,550,142; 7,163,681
   For example in U.S. Pat. No. 7,550,142—an antibody having human heavy chain and human light chain variable regions comprising the amino acid sequences shown in SEQ ID NO: 7 and SEQ ID NO: 8.
 
Seattle Genetics: 15H3 (Ryan M C., et al Cancer Res Apr. 15, 2012; 72(8 Supplement): 4630)
 
(41) CEACAM5 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5)
 
Nucleotide
 
Genbank accession no M17303
 
Genbank version no. M17303.1 GI:178676
 
Genbank record update date: Jun. 23, 2010 08:47 AM
 
Polypeptide
 
Genbank accession no. AAB59513
 
Genbank version no. AAB59513.1 G1:178677
 
Genbank record update date: Jun. 23, 2010 08:47 AM
 
Cross References
 
Beauchemin N., et al  Mol. Cell. Biol.  7 (9), 3221-3230 (1987)
 
Other Information
 
Official Symbol: CEACAM5
 
Other Aliases: CD66e, CEA
 
Other Designations: meconium antigen 100
 
Antibodies
 
AstraZeneca-MedImmune: US 20100330103; US20080057063;
   US20020142359
           for example an antibody having complementarity determining regions (CDRs) with the following sequences: heavy chain; CDR1—DNYMH, CDR2—WIDPENGDTE YAPKFRG, CDR3—LIYAGYLAMD Y; and light chain CDR1—SASSSVTYMH, CDR2—STSNLAS, CDR3—QQRSTYPLT.   Hybridoma 806.077 deposited as European Collection of Cell Cultures (ECACC) deposit no. 96022936.
 
Research Corporation Technologies, Inc.: U.S. Pat. No. 5,047,507
 
Bayer Corporation: U.S. Pat. No. 6,013,772
 
BioAlliance: U.S. Pat. Nos. 7,982,017; 7,674,605
   
   U.S. Pat. No. 7,674,605
           an antibody comprising the heavy chain variable region sequence from the amino acid sequence of SEQ ID NO: 1, and the light chain variable region sequence from the amino acid sequence of SEQ ID NO:2.   an antibody comprising the heavy chain variable region sequence from the amino acid sequence of SEQ ID NO:5, and the light chain variable region sequence from the amino acid sequence of SEQ ID NO:6.
 
Celltech Therapeutics Limited: U.S. Pat. No. 5,877,293
 
The Dow Chemical Company: U.S. Pat. Nos. 5,472,693; 6,417,337; 6,333,405
   
   U.S. Pat. No. 5,472,693—for example, ATCC No. CRL-11215   U.S. Pat. No. 6,417,337—for example, ATCC CRL-12208   U.S. Pat. No. 6,333,405—for example, ATCC CRL-12208
 
Immunomedics, Inc: U.S. Pat. Nos. 7,534,431; 7,230,084; 7,300,644; 6,730,300;
   US20110189085
           an antibody having CDRs of the light chain variable region comprise: CDR1 comprises KASQDVGTSVA (SEQ ID NO: 20); CDR2 comprises WTSTRHT (SEQ ID NO: 21); and CDR3 comprises QQYSLYRS (SEQ ID NO: 22);   and the CDRs of the heavy chain variable region of said anti-CEA antibody comprise: CDR1 comprises TYWMS (SEQ ID NO: 23); CDR2 comprises EIHPDSSTINYAPSLKD (SEQ ID NO: 24); and CDR3 comprises LYFGFPWFAY (SEQ ID NO: 25).   
   US20100221175; US20090092598; US20070202044; US20110064653;   US20090185974; US20080069775.
 
(42) MET (Met Proto-Oncogene; Hepatocyte Growth Factor Receptor)
 
Nucleotide
 
Genbank accession no M35073
 
Genbank version no. M35073.1 GI:187553
 
Genbank record update date: Mar. 6, 2012 11:12 AM
 
Polypeptide
 
Genbank accession no. AAA59589
 
Genbank version no. AAA59589.1 GI:553531
 
Genbank record update date: Mar. 6, 2012 11:12 AM
 
Cross References
 
Dean M., et al  Nature  318 (6044), 385-388 (1985)
 
Other Information
 
Official Symbol: MET
 
Other Aliases: AUTS9, HGFR, RCCP2, c-Met
 
Other Designations: HGF receptor; HGF/SF receptor; SF receptor; hepatocyte growth factor receptor; met proto-oncogene tyrosine kinase; proto-oncogene c-Met; scatter factor receptor; tyrosine-protein kinase Met
 
Antibodies
 
Abgenix/Pfizer: US20100040629
   for example, the antibody produced by hybridoma 13.3.2 having American Type Culture Collection (ATCC) accession number PTA-5026; the antibody produced by hybridoma 9.1.2 having ATCC accession number PTA-5027; the antibody produced by hybridoma 8.70.2 having ATCC accession number PTA-5028; or the antibody produced by hybridoma 6.90.3 having ATCC accession number PTA-5029.
 
Amgen/Pfizer: US20050054019
   for example, an antibody comprising a heavy chain having the amino acid sequences set forth in SEQ ID NO: 2 where X2 is glutamate and X4 is serine and a light chain having the amino acid sequence set forth in SEQ ID NO: 4 where X8 is alanine, without the signal sequences; an antibody comprising a heavy chain having the amino acid sequences set forth in SEQ ID NO: 6 and a light chain having the amino acid sequence set forth in SEQ ID NO: 8, without the signal sequences; an antibody comprising a heavy chain having the amino acid sequences set forth in SEQ ID NO: 10 and a light chain having the amino acid sequence set forth in SEQ ID NO: 12, without the signal sequences; or an antibody comprising a heavy chain having the amino acid sequences set forth in SEQ ID NO: 14 and a light chain having the amino acid sequence set forth in SEQ ID NO: 16, without the signal sequences.
 
Agouron Pharmaceuticals (Now Pfizer): US20060035907
 
Eli Lilly: US20100129369
 
Genentech: U.S. Pat. No. 5,686,292; US20100028337; US20100016241; US20070129301; US20070098707; US20070092520, US20060270594; US20060134104; US20060035278; US20050233960; US20050037431
   U.S. Pat. No. 5,686,292—for example, ATCC HB-11894 and ATCC HB-11895   US 20100016241—for example, ATCC HB-11894 (hybridoma 1A3.3.13) or HB-11895 (hybridoma 5D5.11.6)
 
National Defense Medical Center, Taiwan: Lu R M., et al Biomaterials. 2011 April; 32(12):3265-74.
 
Novartis: US20090175860
   for example, an antibody comprising the sequences of CDR1, CDR2 and CDR3 of heavy chain 4687, wherein the sequences of CDR1, CDR2, and CDR3 of heavy chain 4687 are residues 26-35, 50-65, and 98-102, respectively, of SEQ ID NO: 58; and the sequences of CDR1, CDR2, and CDR3 of light chain 5097, wherein the sequences of CDR1, CDR2, and CDR3 of light chain 5097 are residues 24-39, 55-61, and 94-100 of SEQ ID NO: 37.
 
Pharmacia Corporation: US20040166544
 
Pierre Fabre: US20110239316, US20110097262, US20100115639
 
Sumsung: US 20110129481—for example a monoclonal antibody produced from a hybridoma cell having accession number KCLRF-BP-00219 or accession number of KCLRF-BP-00223.
 
Samsung: US 20110104176—for example an antibody produced by a hybridoma cell having Accession Number: KCLRF-BP-00220.
 
University of Turin Medical School: DN-30 Pacchiana G., et al  J Biol Chem.  2010 Nov. 12; 285(46):36149-57
 
Van Andel Research Institute: Jiao Y., et al  Mol Biotechnol.  2005 September; 31(1):41-54.
 
(43) MUC1 (Mucin 1, Cell Surface Associated)
 
Nucleotide
 
Genbank accession no J05581
 
Genbank version no. J05581.1 GI:188869
 
Genbank record update date: Jun. 23, 2010 08:48 AM
 
Polypeptide
 
Genbank accession no. AAA59876
 
Genbank version no. AAA59876.1 G1:188870
 
Genbank record update date: Jun. 23, 2010 08:48 AM
 
Cross References
 
Gendler S. J., et al  J. Biol. Chem.  265 (25), 15286-15293 (1990)
 
Other Information
 
Official Symbol: MUC1
 
Other Aliases: RP11-263K19.2, CD227, EMA, H23AG, KL-6, MAM6, MUC-1, MUC-1/SEC, MUC-1/X, MUC1/ZD, PEM, PEMT, PUM
 
Other Designations: DF3 antigen; H23 antigen; breast carcinoma-associated antigen DF3; carcinoma-associated mucin; episialin; krebs von den Lungen-6; mucin 1, transmembrane; mucin-1; peanut-reactive urinary mucin; polymorphic epithelial mucin; tumor associated epithelial mucin; tumor-associated epithelial membrane antigen; tumor-associated mucin
 
Antibodies
 
AltaRex—Quest Pharma Tech: U.S. Pat. No. 6,716,966—for example an Alt-1 antibody produced by the hybridoma ATCC No PTA-975.
 
AltaRex—Quest Pharma Tech: U.S. Pat. No. 7,147,850
 
CRT: 5E5—Sorensen A L., et al  Glycobiology  vol. 16 no. 2 pp. 96-107, 2006; HMFG2—Burchell J., et al  Cancer Res.,  47, 5476-5482 (1987); see WO2015/159076
 
Glycotope GT-MAB: GT-MAB 2.5-GEX (Website: http://www.glycotope.com/pipeline/pankomab-gex)
 
Immunogen: U.S. Pat. No. 7,202,346
   for example, antibody MJ-170: hybridoma cell line MJ-170 ATCC accession no. PTA-5286Monoclonal antibody MJ-171: hybridoma cell line MJ-171 ATCC accession no. PTA-5287; monoclonal antibody MJ-172: hybridoma cell line MJ-172 ATCC accession no. PTA-5288; or monoclonal antibody MJ-173: hybridoma cell line MJ-173 ATCC accession no. PTA-5302
 
Immunomedics: U.S. Pat. No. 6,653,104
 
Ramot Tel Aviv Uni: U.S. Pat. No. 7,897,351
 
Regents Uni. CA: U.S. Pat. No. 7,183,388; US20040005647; US20030077676.
 
Roche GlycArt: U.S. Pat. No. 8,021,856
 
Russian National Cancer Research Center: Imuteran—Ivanov P K., et al  Biotechnol J.  2007 July; 2(7):863-70
 
Technische Univ Braunschweig: (IIB6, HT186-B7, HT186-D11, HT186-G2, HT200-3A-C1, HT220-M-D1, HT220-M-G8)—Thie H., et al  PLoS One.  2011 Jan. 14; 6(1):e15921
 
(44) CA9 (Carbonic Anhydrase IX)
 
Nucleotide
 
Genbank accession no. X66839
 
Genbank version no. X66839.1 GI:1000701
 
Genbank record update date: Feb. 2, 2011 10:15 AM
 
Polypeptide
 
Genbank accession no. CAA47315
 
Genbank version no. CAA47315.1 G1:1000702
 
Genbank record update date: Feb. 2, 2011 10:15 AM
 
Cross References
 
Pastorek J., et al  Oncogene  9 (10), 2877-2888 (1994)
 
Other Information
 
Official Symbol: CA9
 
Other Aliases: CAIX, MN
 
Other Designations: CA-IX; P54/58N; RCC-associated antigen G250; RCC-associated protein G250; carbonate dehydratase IX;  carbonic anhydrase  9; carbonic dehydratase; membrane antigen MN; pMW1; renal cell carcinoma-associated antigen G250
 
Antibodies
 
Abgenix/Amgen: US20040018198
 
Affibody: Anti-CAIX Affibody molecules
   (http://www.affibody.com/en/Product-Portfolio/Pipeline/)
 
Bayer: U.S. Pat. No. 7,462,696
 
Bayer/Morphosys: 3ee9 mAb—Petrul H M., et al  Mol Cancer Ther.  2012 February; 11(2):340-9
 
Harvard Medical School: Antibodies G10, G36, G37, G39, G45, G57, G106, G119, G6, G27, G40 and G125. Xu C., et al  PLoS One.  2010 Mar. 10; 5(3):e9625
 
Institute of Virology, Slovak Academy of Sciences (Bayer)—U.S. Pat. No. 5,955,075
   for example, M75—ATCC Accession No. HB 11128 or MN12—ATCC Accession No. HB 11647
 
Institute of Virology, Slovak Academy of Sciences: U.S. Pat. No. 7,816,493
   for example the M75 monoclonal antibody that is secreted from the hybridoma VU-M75, which was deposited at the American Type Culture Collection under ATCC No. HB 11128; or the V/10 monoclonal antibody secreted from the hybridoma V/10-VU, which was deposited at the International Depository Authority of the Belgian Coordinated Collection of Microorganisms (BCCM) at the Laboratorium voor Moleculaire Bioloqie-Plasmidencollectie (LMBP) at the Universeit Gent in Gent, Belgium, under Accession No. LMBP 6009CB.
 
Institute of Virology, Slovak Academy of Sciences US20080177046; US20080176310; US20080176258; US20050031623
 
Novartis: US20090252738
 
Wilex: U.S. Pat. No. 7,691,375—for example the antibody produced by the hybridoma cell line DSM ASC 2526.
 
Wilex: US20110123537; Rencarex: Kennett R H., et al  Curr Opin Mol Ther.  2003 February; 5(1):70-5
 
Xencor: US20090162382
 
(45) EGFRvIII (Epidermal Growth Factor Receptor (EGFR),  Transcript Variant  3,
 
Nucleotide
 
Genbank accession no. NM_201283
 
Genbank version no. NM_201283.1 G1:41327733
 
Genbank record update date: Sep. 30, 2012 01:47 PM
 
Polypeptide
 
Genbank accession no. NP_958440
 
Genbank version no. NP_958440.1 G1:41327734
 
Genbank record update date: Sep. 30, 2012 01:47 PM
 
Cross-References
 
Batra S K., et al  Cell Growth Differ  1995; 6:1251-1259.
 
Antibodies:
 
U.S. Pat. Nos. 7,628,986 and 7,736,644 (Amgen)
   For example, a heavy chain variable region amino acid sequence selected from the group consisting of SEQ ID NO: 142 and variants & a light chain variable region amino acid sequence selected from the group consisting of: SEQ ID NO: 144 and variants.
 
US20100111979 (Amgen)
   For example, an antibody comprising a heavy chain amino acid sequence comprising:   CDR1 consisting of a sequence selected from the group consisting of the amino acid sequences for the CDR1 region of antibodies 13.1.2 (SEQ ID NO: 138), 131 (SEQ ID NO: 2), 170 (SEQ ID NO: 4), 150 (SEQ ID NO: 5), 095 (SEQ ID NO: 7), 250 (SEQ ID NO: 9), 139 (SEQ ID NO: 10), 211 (SEQ ID NO: 12), 124 (SEQ ID NO: 13), 318 (SEQ ID NO: 15), 342 (SEQ ID NO: 16), and 333 (SEQ ID NO: 17);   CDR2 consisting of a sequence selected from the group consisting of the amino acid sequences for the CDR2 region of antibodies 13.1.2 (SEQ ID NO: 138), 131 (SEQ ID NO: 2), 170 (SEQ ID NO: 4), 150 (SEQ ID NO: 5), 095 (SEQ ID NO: 7), 250 (SEQ ID NO: 9), 139 (SEQ ID NO: 10), 211 (SEQ ID NO: 12), 124 (SEQ ID NO: 13), 318 (SEQ ID NO: 15), 342 (SEQ ID NO: 16), and 333 (SEQ ID NO: 17); and   CDR3 consisting of a sequence selected from the group consisting of the amino acid sequences for the CDR3 region of antibodies 13.1.2 (SEQ ID NO: 138), 131 (SEQ ID NO: 2), 170 (SEQ ID NO: 4), 150 (SEQ ID NO: 5), 095 (SEQ ID NO: 7), 250 (SEQ ID NO: 9), 139 (SEQ ID NO: 10), 211 (SEQ ID NO: 12), 124 (SEQ ID NO: 13), 318 (SEQ ID NO: 15), 342 (SEQ ID NO: 16), and 333 (SEQ ID NO: 17).
 
US20090240038 (Amgen)
   For example, an antibody having at least one of the heavy or light chain polypeptides comprises an amino acid sequence that is at least 90% identical to the amino acid sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 19, SEQ ID NO: 142, SEQ ID NO: 144, and any combination thereof.
 
US20090175887 (Amgen)
   For example, an antibody having a heavy chain amino acid sequence selected from the group consisting of the heavy chain amino acid sequence of antibody 13.1.2 (SEQ ID NO: 138), 131 (SEQ ID NO: 2), 170 (SEQ ID NO: 4), 150 (SEQ ID NO: 5), 095 (SEQ ID NO: 7), 250 (SEQ ID NO: 9), 139 (SEQ ID NO: 10), 211 (SEQ ID NO: 12), 124 (SEQ ID NO: 13), 318 (SEQ ID NO: 15), 342 (SEQ ID NO: 16), and 333 (SEQ ID NO: 17).
 
US20090156790 (Amgen)
   For example, antibody having heavy chain polypeptide and a light chain polypeptide, wherein at least one of the heavy or light chain polypeptides comprises an amino acid sequence that is at least 90% identical to the amino acid sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 19, SEQ ID NO: 142, SEQ ID NO: 144, and any combination thereof.
 
US20090155282, US20050059087 and US20050053608 (Amgen)
   For example, an antibody heavy chain amino acid sequence selected from the group consisting of the heavy chain amino acid sequence of antibody 13.1.2 (SEQ ID NO: 138), 131 (SEQ ID NO: 2), 170 (SEQ ID NO: 4), 150 (SEQ ID NO: 5), 095 (SEQ ID NO: 7), 250 (SEQ ID NO: 9), 139 (SEQ ID NO: 10), 211 (SEQ ID NO: 12), 124 (SEQ ID NO: 13), 318 (SEQ ID NO: 15), 342 (SEQ ID NO: 16), and 333 (SEQ ID NO: 17).
 
MR1-1 (U.S. Pat. No. 7,129,332; Duke)
   For example, a variant antibody having the sequence of SEQ ID NO.18 with the substitutions S98P-T99Y in the CDR3 VH, and F92W in CDR3 VL.
 
L8A4, H10, Y10 (Wikstrand C J., et al  Cancer Res.  1995 Jul. 15; 55(14):3140-8; Duke)
 
US20090311803 (Harvard University)
   For example, SEQ ID NO:9 for antibody heavy chain variable region, and SEQ ID NO: 3 for light chain variable region amino acid sequences
 
US20070274991 (EMD72000, also known as matuzumab; Harvard University)
   For example, SEQ ID NOs: 3 & 9 for light chain and heavy chain respectively
 
U.S. Pat. No. 6,129,915 (Schering)
   For example, SEQ. ID NOs: 1, 2, 3, 4, 5 and 6.
 
mAb CH12—Wang H., et al  FASEB J.  2012 January; 26(1):73-80 (Shanghai Cancer Institute).
 
RAbDMvIII—Gupta P., et al  BMC Biotechnol.  2010 Oct. 7; 10:72 (Stanford University Medical Center).
 
mAb Ua30—Ohman L., et al Tumour Biol. 2002 March-April; 23(2):61-9 (Uppsala University).
 
Han DG., et al  Nan Fang Yi Ke Da Xue Xue Bao.  2010 January; 30(1):25-9 (Xi'an Jiaotong University).
 
(46) Cd33 (Cd33 Molecule)
 
Nucleotide
 
Genbank accession no. M_23197
 
Genbank version no. NM_23197.1 G1:180097
 
Genbank record update date: Jun. 23, 2010 08:47 AM
 
Polypeptide
 
Genbank accession no. AAA51948
 
Genbank version no. AAA51948.1 G1:188098
 
Genbank record update date: Jun. 23, 2010 08:47 AM
 
Cross-References
 
Simmons D., et al  J. Immunol.  141 (8), 2797-2800 (1988)
 
Other Information
 
Official Symbol: CD33
 
Other Aliases: SIGLEC-3, SIGLEC3, p67
 
Other Designations: CD33 antigen (gp67); gp67; myeloid cell surface antigen CD33; sialic acid binding Ig- like lectin  3; sialic acid-binding Ig-like lectin
 
Antibodies
 
H195 (Lintuzumab)—Raza A., et al  Leuk Lymphoma.  2009 August; 50(8):1336-44; U.S. Pat. No. 6,759,045 (Seattle Genetics/Immunomedics)
 
mAb OKT9: Sutherland, D. R. et al.  Proc Natl Acad Sci USA  78(7): 4515-4519 1981, Schneider, C., et al  J Biol Chem  257, 8516-8522 (1982)
 
mAb E6: Hoogenboom, H. R., et al  J Immunol  144, 3211-3217 (1990)
 
U.S. Pat. No. 6,590,088 (Human Genome Sciences)
   For example, SEQ ID NOs: 1 and 2 and ATCC accession no. 97521
 
U.S. Pat. No. 7,557,189 (Immunogen)
   For example, an antibody or fragment thereof comprising a heavy chain variable region which comprises three CDRs having the amino acid sequences of SEQ ID NOs:1-3 and a light chain variable region comprising three CDRs having the amino acid sequences of SEQ ID NOs:4-6.
 
(47) Cd19 (Cd19 Molecule)
 
Nucleotide
 
Genbank accession no. NM_001178098
 
Genbank version no. NM_001178098.1 G1:296010920
 
Genbank record update date: Sep. 10, 2012 12:43 AM
 
Polypeptide
 
Genbank accession no. NP_001171569
 
Genbank version no. NP_001171569.1 G1:296010921
 
Genbank record update date: Sep. 10, 2012 12:43 AM
 
Cross-References
 
Tedder T F., et al J. Immunol. 143 (2): 712-7 (1989)
 
Other Information
 
Official Symbol: CD19
 
Other Aliases: B4, CVID3
 
Other Designations: B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; T-cell surface antigen Leu-12; differentiation antigen CD19
 
Antibodies
 
Immunogen: HuB4—Al-Katib A M., et al  Clin Cancer Res.  2009 Jun. 15; 15(12):4038-45.
 
4G7: Kügler M., et al  Protein Eng Des Sel.  2009 March; 22(3):135-47
   For example, sequences in FIG. 3 of Knappik, A. et al.  J Mol Biol  2000 February; 296(1):57-86
 
AstraZeneca/MedImmune: MEDI-551—Herbst R., et al  J Pharmacol Exp Ther.  2010 October; 335(1):213-22
 
Glenmark Pharmaceuticals: GBR-401—Hou S., et al Mol Cancer Ther November 2011 (Meeting Abstract Supplement) C164
 
U.S. Pat. No. 7,109,304 (Immunomedics)
   For example, an antibody comprising the sequence of hA19Vk (SEQ ID NO:7) and the sequence of hA19VH (SEQ ID NO:10)
 
U.S. Pat. No. 7,902,338 (Immunomedics)
   For example, an antibody or antigen-binding fragment thereof that comprises the light chain complementarity determining region CDR sequences CDR1 of SEQ ID NO: 16 (KASQSVDYDGDSYLN); CDR2 of SEQ ID NO: 17 (DASNLVS); and CDR3 of SEQ ID NO: 18 (QQSTEDPWT) and the heavy chain CDR sequences CDR1 of SEQ ID NO: 19 (SYWMN); CDR2 of SEQ ID NO: 20 (QIWPGDGDTNYNGKFKG) and CDR3 of SEQ ID NO: 21 (RETTTVGRYYYAMDY) and also comprises human antibody framework (FR) and constant region sequences with one or more framework region amino acid residues substituted from the corresponding framework region sequences of the parent murine antibody, and wherein said substituted FR residues comprise the substitution of serine for phenylalanine at Kabat residue 91 of the heavy chain variable region.
 
Medarex: MDX-1342—Cardarelli P M., et al  Cancer Immunol Immunother.  2010 February; 59(2):257-65.
 
MorphoSys/Xencor: MOR-208/XmAb-5574—Zalevsky J., et al  Blood.  2009 Apr. 16; 113(16):3735-43
 
U.S. Pat. No. 7,968,687 (Seattle Genetics)
   An antibody or antigen-binding fragment comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:9 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 24.
 
4G7 chim—Lang P., et al Blood. 2004 May 15; 103(10):3982-5 (University of Tübingen)
   For example, FIG. 6 and SEQ ID No: 80 of US20120082664
 
Zhejiang University School of Medicine: 2E8—Zhang J., et al J Drug Target. 2010 November; 18(9):675-8
 
(48) IL2RA (Interleukin 2 Receptor, Alpha); NCBI Reference Sequence: NM_000417.2);
 
Nucleotide
 
Genbank accession no. NM_000417
 
Genbank version no. NM_000417.2 GI:269973860
 
Genbank record update date: Sep. 9, 2012 04:59 PM
 
Polypeptide
 
Genbank accession no. NP_000408
 
Genbank version no. NP_000408.1 G1:4557667
 
Genbank record update date: Sep. 9, 2012 04:59 PM
 
Cross-References
 
Kuziel W. A., et al  J. Invest. Dermatol.  94 (6 SUPPL), 27S-32S (1990)
 
Other Information
 
Official Symbol: IL2RA
 
Other Aliases: RP11-536K7.1, CD25, IDDM10, IL2R, TCGFR
 
Other Designations: FIL-2 receptor subunit alpha; IL-2-RA; IL-2R subunit alpha; IL2-RA; TAC antigen; interleukin-2 receptor subunit alpha; p55
 
Antibodies
 
U.S. Pat. No. 6,383,487 (Novartis/UCL: Baxilisimab [Simulect])
 
U.S. Pat. No. 6,521,230 (Novartis/UCL: Baxilisimab [Simulect])
   For example, an antibody having an antigen binding site comprises at least one domain which comprises CDR1 having the amino acid sequence in SEQ. ID. NO: 7, CDR2 having the amino acid sequence in SEQ. ID. NO: 8, and CDR3 chaving the amino acid sequence in SEQ. ID. NO: 9; or said CDR1, CDR2 and CDR3 taken in sequence as a whole comprise an amino acid sequence which is at least 90% identical to SEQ. ID. NOs: 7, 8 and 9 taken in sequence as a whole.
 
Daclizumab—Rech A J., et al  Ann N Y Acad Sci.  2009 September; 1174:99-106 (Roche)
 
(49) AXL (AXL Receptor Tyrosine Kinase)
 
Nucleotide
 
Genbank accession no. M76125
 
Genbank version no. M76125.1 G1:292869
 
Genbank record update date: Jun. 23, 2010 08:53 AM
 
Polypeptide
 
Genbank accession no. AAA61243
 
Genbank version no. AAA61243.1 G1:29870
 
Genbank record update date: Jun. 23, 2010 08:53 AM
 
Cross-References
 
O'Bryan J. P., et al  Mol. Cell. Biol.  11 (10), 5016-5031 (1991); Bergsagel P. L., et al  J. Immunol.  148 (2), 590-596 (1992)
 
Other Information
 
Official Symbol: AXL
 
Other Aliases: JTK11, UFO
 
Other Designations: AXL oncogene; AXL transforming sequence/gene; oncogene AXL; tyrosine-protein kinase receptor UFO
 
Antibodies
 
YW327.6S2—Ye X., et al  Oncogene.  2010 Sep. 23; 29(38):5254-64. (Genentech)
 
BergenBio: BGB324 (http://www.bergenbio.com/BGB324)
 
(50) CD30—TNFRSF8 (Tumor Necrosis Factor Receptor Superfamily, Member 8)
 
Nucleotide
 
Genbank accession no. M83554
 
Genbank version no. M83554.1 G1:180095
 
Genbank record update date: Jun. 23, 2010 08:53 AM
 
Polypeptide
 
Genbank accession no. AAA51947
 
Genbank version no. AAA51947.1 G1:180096
 
Genbank record update date: Jun. 23, 2010 08:53 AM
 
Cross-References
 
Durkop H., et al  Cell  68 (3), 421-427 (1992)
 
Other Information
 
Official Symbol: TNFRSF8
 
Other Aliases: CD30, D1S166E, Ki-1
 
Other Designations: CD30L receptor; Ki-1 antigen; cytokine receptor CD30; lymphocyte activation antigen CD30; tumor necrosis factor  receptor superfamily member  8
 
(51) BCMA (B-Cell Maturation Antigen)—TNFRSF17 (Tumor Necrosis Factor Receptor Superfamily, Member 17)
 
Nucleotide
 
Genbank accession no. Z29574
 
Genbank version no. Z29574.1 GI:471244
 
Genbank record update date: Feb. 2, 2011 10:40 AM
 
Polypeptide
 
Genbank accession no. CAA82690
 
Genbank version no. CAA82690.1 GI:471245
 
Genbank record update date: Feb. 2, 2011 10:40 AM
 
Cross-References
 
Laabi Y., et al Nucleic Acids Res. 22 (7), 1147-1154 (1994)
 
Other Information
 
Official Symbol: TNFRSF17
 
Other Aliases: BCM, BCMA, CD269
 
Other Designations: B cell maturation antigen; B-cell maturation factor; B-cell maturation protein; tumor necrosis factor receptor superfamily member 17
 
(52) CT Ags—CTA (Cancer Testis Antigens)
 
Cross-References
 
Fratta E., et al.  Mol Oncol.  2011 April; 5(2):164-82; Lim S H., at al Am J Blood Res. 2012; 2(1):29-35.
 
(53) CD174 (Lewis Y)—FUT3 (Fucosyltransferase 3 (Galactoside 3(4)-L-Fucosyltransferase, Lewis Blood Group)
 
Nucleotide
 
Genbank accession no. NM000149
 
Genbank version no. NM000149.3 GI:148277008
 
Genbank record update date: Jun. 26, 2012 04:49 PM
 
Polypeptide
 
Genbank accession no. NP_000140
 
Genbank version no. NP_000140.1 G1:4503809
 
Genbank record update date: Jun. 26, 2012 04:49 PM
 
Cross-References
 
Kukowska-Latallo, J. F., et al  Genes Dev.  4 (8), 1288-1303 (1990)
 
Other Information
 
Official Symbol: FUT3
 
Other Aliases: CD174, FT3B, FucT-III, LE, Les
 
Other Designations: Lewis FT; alpha-(1,3/1,4)-fucosyltransferase; blood group Lewis alpha-4-fucosyltransferase; fucosyltransferase III; galactoside 3(4)-L-fucosyltransferase
 
(54) CLEC14A (C-Type Lectin Domain Family 14, Member a; Genbank Accession No. NM175060)
 
Nucleotide
 
Genbank accession no. NM175060
 
Genbank version no. NM175060.2 G1:371123930
 
Genbank record update date: Apr. 1, 2012 03:34 PM
 
Polypeptide
 
Genbank accession no. NP_778230
 
Genbank version no. NP_778230.1 G1:28269707
 
Genbank record update date: Apr. 1, 2012 03:34 PM
 
Other Information
 
Official Symbol: CLEC14A
 
Other Aliases: UNQ236/PRO269, C14orf27, CEG1, EGFR-5
 
Other Designations: C-type lectin domain family 14 member A; CIECT and EGF-like domain containing protein; epidermal growth factor receptor 5
 
(55) GRP78—HSPA5 (Heat Shock 70 kDa Protein 5 (Glucose-Regulated Protein, 78 kDa)
 
Nucleotide
 
Genbank accession no. NM005347
 
Genbank version no. NM005347.4 G1:305855105
 
Genbank record update date: Sep. 30, 2012 01:42 PM
 
Polypeptide
 
Genbank accession no. NP_005338
 
Genbank version no. NP_005338.1 GI:16507237
 
Genbank record update date: Sep. 30, 2012 01:42 PM
 
Cross-References
 
Ting J., et al DNA 7 (4), 275-286 (1988)
 
Other Information
 
Official Symbol: HSPA5
 
Other Aliases: BIP, GRP78, MIF2
 
Other Designations: 78 kDa glucose-regulated protein; endoplasmic reticulum lumenal Ca(2+)-binding protein grp78; immunoglobulin heavy chain-binding protein
 
(56) Cd70 (Cd70 Molecule) L08096
 
Nucleotide
 
Genbank accession no. L08096
 
Genbank version no. L08096.1 GI:307127
 
Genbank record update date: Jun. 23, 2012 08:54 AM
 
Polypeptide
 
Genbank accession no. AAA36175
 
Genbank version no. AAA36175.1 GI:307128
 
Genbank record update date: Jun. 23, 2012 08:54 AM
 
Cross-References
 
Goodwin R. G., et al  Cell  73 (3), 447-456 (1993)
 
Other Information
 
Official Symbol: CD70
 
Other Aliases: CD27L, CD27LG, TNFSF7
 
Other Designations: CD27 ligand; CD27-L; CD70 antigen; Ki-24 antigen; surface antigen CD70; tumor necrosis factor (ligand) superfamily, member 7; tumor necrosis factor ligand superfamily member 7
 
Antibodies
 
MDX-1411 against CD70 (Medarex)
 
h1F6 (Oflazoglu, E., et al, Clin Cancer Res. 2008 Oct. 1; 14(19):6171-80; Seattle Genetics)
   For example, see US20060083736 SEQ ID NOs: 1, 2, 11 and 12 and FIG. 1.
 
(57) Stem Cell Specific Antigens. For Example:
   5T4 (see entry (63) below)   CD25 (see entry (48) above)   CD32
           Polypeptide
               Genbank accession no. ABK42161   Genbank version no. ABK42161.1 GI:117616286   Genbank record update date: Jul. 25, 2007 03:00 PM   
   
   LGR5/GPR49
           Nucleotide
               Genbank accession no. NM_003667   Genbank version no. NM_003667.2 G1:24475886   Genbank record update date: Jul. 22, 2012 03:38 PM   
   Polypeptide
               Genbank accession no. NP_003658   Genbank version no. NP_003658.1 G1:4504379   Genbank record update date: Jul. 22, 2012 03:38 PM   
   
   Prominin/CD133
           Nucleotide
               Genbank accession no. NM_006017   Genbank version no. NM_006017.2 G1:224994187   Genbank record update date: Sep. 30, 2012 01:47 PM   
   Polypeptide
               Genbank accession no. NP_006008   Genbank version no. NP_006008.1 G1:5174387   Genbank record update date: Sep. 30, 2012 01:47 PM
 
(58) ASG-5
 
Cross-References
 
(Smith L. M., et. al  AACR  2010  Annual Meeting  (abstract #2590); Gudas J. M., et. al.  AACR  2010  Annual Meeting  (abstract #4393)
 
Antibodies
 
Anti-AGS-5 Antibody: M6.131 (Smith, L. M., et. al  AACR  2010  Annual Meeting  (abstract #2590)
 
(59) ENPP3 (Ectonucleotide Pyrophosphatase/Phosphodiesterase 3)
 
Nucleotide
 
Genbank accession no. AF005632
 
Genbank version no. AF005632.2 G1:4432589
 
Genbank record update date: Mar. 10, 2010 09:41 PM
 
Polypeptide
 
Genbank accession no. AAC51813
 
Genbank version no. AAC51813.1 G1:2465540
 
Genbank record update date: Mar. 10, 2010 09:41 PM
 
Cross-References
 
Jin-Hua P., et al  Genomics  45 (2), 412-415 (1997)
 
Other Information
 
Official Symbol: ENPP3
 
Other Aliases: RP5-988G15.3, B10, CD203c, NPP3, PD-IBETA, PDNP3
 
Other Designations:  E-NPP  3; dJ1005H11.3 (phosphodiesterase I/nucleotide pyrophosphatase 3); dJ914N13.3 (phosphodiesterase I/nucleotide pyrophosphatase 3); ectonucleotide pyrophosphatase/ phosphodiesterase family member  3; gp130RB13-6; phosphodiesterase I beta; phosphodiesterase I/ nucleotide pyrophosphatase  3; phosphodiesterase-I beta
 
(60) PRR4 (Proline Rich 4 (Lacrimal))
 
Nucleotide
 
Genbank accession no. NM_007244
 
Genbank version no. NM_007244.2 G1:154448885
 
Genbank record update date: Jun. 28, 2012 12:39 PM
 
Polypeptide
 
Genbank accession no. NP_009175
 
Genbank version no. NP_009175.2 G1:154448886
 
Genbank record update date: Jun. 28, 2012 12:39 PM
 
Cross-References
 
Dickinson D. P., et al  Invest. Ophthalmol. Vis. Sci.  36 (10), 2020-2031 (1995)
 
Other Information
 
Official Symbol: PRR4
 
Other Aliases: LPRP, PROL4
 
Other Designations: lacrimal proline-rich protein; nasopharyngeal carcinoma-associated proline- rich protein  4; proline- rich polypeptide  4; proline- rich protein  4
 
(61) GCC—GUCY2C (Guanylate Cyclase 2C (Heat Stable Enterotoxin Receptor)
 
Nucleotide
 
Genbank accession no. NM_004963
 
Genbank version no. NM_004963.3 G1:222080082
 
Genbank record update date: Sep. 2, 2012 01:50 PM
 
Polypeptide
 
Genbank accession no. NP_004954
 
Genbank version no. NP_004954.2 G1:222080083
 
Genbank record update date: Sep. 2, 2012 01:50 PM
 
Cross-References
 
De Sauvage F. J., et al  J. Biol. Chem.  266 (27), 17912-17918 (1991); Singh S., et al  Biochem. Biophys. Res. Commun.  179 (3), 1455-1463 (1991)
 
Other Information
 
Official Symbol: GUCY2C
 
Other Aliases: DIAR6, GUC2C, MUCIL, STAR
 
Other Designations: GC-C; STA receptor; guanylyl cyclase C; hSTAR; heat-stable enterotoxin receptor; intestinal guanylate cyclase
 
(62) Liv-1—SLC39A6 (Solute Carrier Family 39 (Zinc Transporter), Member 6)
 
Nucleotide
 
Genbank accession no. U41060
 
Genbank version no. U41060.2 GI:12711792
 
Genbank record update date: Nov. 30, 2009 04:35 PM
 
Polypeptide
 
Genbank accession no. AAA96258
 
Genbank version no. AAA96258.2 GI:12711793
 
Genbank record update date: Nov. 30, 2009 04:35 PM
 
Cross-References
 
Taylor KM., et al  Biochim Biophys Acta.  2003 Apr. 1; 1611(1-2):16-30
 
Other Information
 
Official Symbol: SLC39A6
 
Other Aliases: LIV-1
 
Other Designations: LIV-1 protein, estrogen regulated; ZIP-6; estrogen-regulated protein LIV-1; solute carrier family 39 (metal ion transporter),  member  6;  solute carrier family  39  member  6; zinc transporter ZIP6; zrt- and Irt- like protein  6
 
(63) 5T4, Trophoblast Glycoprotein, TPBG—TPBG (Trophoblast Glycoprotein)
 
Nucleotide
 
Genbank accession no. AJ012159
 
Genbank version no. AJ012159.1 GI:3805946
 
Genbank record update date: Feb. 1, 2011 10:27 AM
 
Polypeptide
 
Genbank accession no. CAA09930
 
Genbank version no. CAA09930.1 GI:3805947
 
Genbank record update date: Feb. 1, 2011 10:27 AM
 
Cross-References
 
King K. W., et al  Biochim. Biophys. Acta  1445 (3), 257-270 (1999)
 
Other Information
   
   
   Official Symbol: TPBG   Other Aliases: 5T4, 5T4AG, M6P1   Other Designations: 5T4 oncofetal antigen; 5T4 oncofetal trophoblast glycoprotein; 5T4 oncotrophoblast glycoprotein   See WO2015/155345
 
(64) CD56—NCMA 1 (Neural Cell Adhesion Molecule 1)
 
Nucleotide
 
Genbank accession no. NM_000615
 
Genbank version no. NM_000615.6 G1:336285433
 
Genbank record update date: Sep. 23, 2012 02:32 PM
 
Polypeptide
 
Genbank accession no. NP_000606
 
Genbank version no. NP_000606.3 G1:94420689
 
Genbank record update date: Sep. 23, 2012 02:32 PM
 
Cross-References
 
Dickson, G., et al,  Cell  50 (7), 1119-1130 (1987)
 
Other Information
 
Official Symbol: NCAM1
 
Other Aliases: CD56, MSK39, NCAM
 
Other Designations: antigen recognized by monoclonal antibody 5.1H11; neural cell adhesion molecule, NCAM
 
Antibodies
 
Immunogen: HuN901 (Smith S V., et al  Curr Opin Mol Ther.  2005 August; 7(4):394-401)
   For example, see humanized from murine N901 antibody. See FIGS. 1b and 1e of Roguska, M. A., et al.  Proc Natl Acad Sci USA  February 1994; 91:969-973.
 
(65) CanAg (Tumor Associated Antigen CA242)
 
Cross-References
 
Haglund C., et al  Br J Cancer  60:845-851, 1989; Baeckstrom D., et al  J Biol Chem  266:21537-21547, 1991
 
Antibodies
 
huC242 (Tolcher A W et al.,  J Clin Oncol.  2003 Jan. 15; 21(2):211-22; Immunogen)
   For example, see US20080138898A1 SEQ ID NO: 1 and 2
 
(66) FOLR1 (Folate Receptor 1)
 
Nucleotide
 
Genbank accession no. J05013
 
Genbank version no. J05013.1 G1:182417
 
Genbank record update date: Jun. 23, 2010 08:47 AM
 
Polypeptide
 
Genbank accession no. AAA35823
 
Genbank version no. AAA35823.1 G1:182418
 
Genbank record update date: Jun. 23, 2010 08:47 AM
 
Cross-References
 
Elwood P. C., et al  J. Biol. Chem.  264 (25), 14893-14901 (1989)
 
Other Information
 
Official Symbol: FOLR1
 
Other Aliases: FBP, FOLR
 
Other Designations: FR-alpha; KB cells FBP; adult folate-binding protein; folate binding protein; folate receptor alpha; folate receptor, adult; ovarian tumor-associated antigen MOv18
 
Antibodies
 
M9346A—Whiteman K R., et al  Cancer Res  Apr. 15, 2012; 72(8 Supplement): 4628 (Immunogen)
 
(67) GPNMB (Glycoprotein (Transmembrane) Nmb)
 
Nucleotide
 
Genbank accession no. X76534
 
Genbank version no. X76534.1 G1:666042
 
Genbank record update date: Feb. 2, 2011 10:10 AM
 
Polypeptide
 
Genbank accession no. CAA54044
 
Genbank version no. CAA54044.1 GI:666043
 
Genbank record update date: Feb. 2, 2011 10:10 AM
 
Cross-References
 
Weterman M. A., et al  Int. J. Cancer  60 (1), 73-81 (1995)
 
Other Information
 
Official Symbol: GPNMB
 
Other Aliases: UNQ1725/PRO9925, HGFIN, NMB
 
Other Designations: glycoprotein NMB; glycoprotein nmb-like protein; osteoactivin; transmembrane glycoprotein HGFIN; transmembrane glycoprotein NMB
 
Antibodies
 
Celldex Therapeutics: CR011 (Tse K F., et al  Clin Cancer Res.  2006 Feb. 15; 12(4):1373-82)
   For example, see EP1827492B1 SEQ ID NO: 22, 24, 26, 31, 33 and 35
 
(68) TIM-1—HAVCR1 (Hepatitis a Virus Cellular Receptor 1)
 
Nucleotide
 
Genbank accession no. AF043724
 
Genbank version no. AF043724.1 GI:2827453
 
Genbank record update date: Mar. 10, 2010 06:24 PM
 
Polypeptide
 
Genbank accession no. AAC39862
 
Genbank version no. AAC39862.1 GI:2827454
 
Genbank record update date: Mar. 10, 2010 06:24 PM
 
Cross-References
 
Feigelstock D., et al  J. Virol.  72 (8), 6621-6628 (1998)
 
Other Information
 
Official Symbol: HAVCR1
 
Other Aliases: HAVCR, HAVCR-1, KIM-1, KIM1, TIM, TIM-1, TIM1, TIMD-1, TIMD1
 
Other Designations: T cell immunoglobin domain and mucin domain protein 1; T-cell membrane protein 1; kidney injury molecule 1
 
(69) RG-1/Prostate Tumor Target Mindin—Mindin/RG-1
 
Cross-References
 
Parry R., et al Cancer Res. 2005 Sep. 15; 65(18):8397-405
 
(70) B7-H4—VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1
 
Nucleotide
 
Genbank accession no. BX648021
 
Genbank version no. BX648021.1 G1:34367180
 
Genbank record update date: Feb. 2, 2011 08:40 AM
 
Cross-References
 
Sica G L., et al  Immunity.  2003 June; 18(6):849-61
 
Other Information
 
Official Symbol: VTCN1
 
Other Aliases: RP11-229A19.4, B7-H4, B7H4, B7S1, B7X, B7h.5, PRO1291, VCTN1
 
Other Designations: B7 family member, H4; B7 superfamily member 1; T cell costimulatory molecule B7x; T-cell costimulatory molecule B7x; V-set domain-containing T-cell activation inhibitor 1; immune costimulatory protein B7-H4
 
(71) PTK7 (PTK7 Protein Tyrosine Kinase 7)
 
Nucleotide
 
Genbank accession no. AF447176
 
Genbank version no. AF447176.1 G1:17432420
 
Genbank record update date: Nov. 28, 2008 01:51 PM
 
Polypeptide
 
Genbank accession no. AAL39062
 
Genbank version no. AAL39062.1 G1:17432421
 
Genbank record update date: Nov. 28, 2008 01:51 PM
 
Cross-References
 
Park S. K., et al  J. Biochem.  119 (2), 235-239 (1996)
 
Other Information
 
Official Symbol: PTK7
 
Other Aliases: CCK-4, CCK4
 
Other Designations:  colon carcinoma kinase  4; inactive tyrosine-protein kinase 7; pseudo tyrosine kinase receptor 7; tyrosine-protein kinase-like 7
 
(72) Cd37 (Cd37 Molecule)
 
Nucleotide
 
Genbank accession no. NM_001040031
 
Genbank version no. NM_001040031.1 G1:91807109
 
Genbank record update date: Jul. 29, 2012 02:08 PM
 
Polypeptide
 
Genbank accession no. NP_001035120
 
Genbank version no. NP_001035120.1 G1:91807110
 
Genbank record update date: Jul. 29, 2012 02:08 PM
 
Cross-References
 
Schwartz-Albiez R., et al  J. Immunol.  140 (3), 905-914 (1988)
 
Other Information
 
Official Symbol: CD37
 
Other Aliases: GP52-40, TSPAN26
 
Other Designations: CD37 antigen; cell differentiation antigen 37; leukocyte antigen CD37; leukocyte surface antigen CD37; tetraspanin-26; tspan-26
 
Antibodies
 
Boehringer Ingelheim: mAb 37.1 (Heider K H., et al  Blood.  2011 Oct. 13; 118(15):4159-68)
 
Trubion: CD37-SMIP (G28-1 scFv-lg) ((Zhao X., et al  Blood.  2007; 110: 2569-2577)
   For example, see US20110171208A1 SEQ ID NO: 253 Immunogen: K7153A (Deckert J., et al Cancer Res Apr. 15, 2012; 72(8 Supplement): 4625)
 
(73) CD138—SDC1 (Syndecan 1)
 
Nucleotide
 
Genbank accession no. AJ551176
 
Genbank version no. AJ551176.1 G1:29243141
 
Genbank record update date: Feb. 1, 2011 12:09 PM
 
Polypeptide
 
Genbank accession no. CAD80245
 
Genbank version no. CAD80245.1 G1:29243142
 
Genbank record update date: Feb. 1, 2011 12:09 PM
 
Cross-References
 
O'Connell FP., et al  Am J Clin Pathol.  2004 February; 121(2):254-63
 
Other Information
 
Official Symbol: SDC1
 
Other Aliases: CD138, SDC, SYND1, syndecan
 
Other Designations: CD138 antigen; heparan sulfate proteoglycan fibroblast growth factor receptor; syndecan proteoglycan 1; syndecan-1
 
Antibodies
 
Biotest: chimerized MAb (nBT062)—(Jagannath S., et al Poster ASH #3060, 2010; WIPO
 
Patent Application WO/2010/128087)
   For example, see US20090232810 SEQ ID NO: 1 and 2
 
Immunogen: B-B4 (Tassone P., et al Blood 104_3688-3696)
   For example, see US20090175863A1 SEQ ID NO: 1 and 2
 
(74) CD74 (CD74 Molecule, Major Histocompatibility Complex, Class II Invariant Chain)
 
Nucleotide
 
Genbank accession no. NM_004355
 
Genbank version no. NM_004355.1 G1:343403784
 
Genbank record update date: Sep. 23, 2012 02:30 PM
 
Polypeptide
 
Genbank accession no. NP_004346
 
Genbank version no. NP_004346.1 G1:10835071
 
Genbank record update date: Sep. 23, 2012 02:30 PM
 
Cross-References
 
Kudo, J., et al  Nucleic Acids Res.  13 (24), 8827-8841 (1985)
 
Other Information
 
Official Symbol: CD74
 
Other Aliases: DHLAG, HLADG, II, la-GAMMA
 
Other Designations: CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated); HLA class II histocompatibility antigen gamma chain; HLA-DR antigens-associated invariant chain; HLA-DR-gamma; la-associated invariant chain; MHC HLA-DR gamma chain; gamma chain of class II antigens; p33
 
Antibodies
 
Immunomedics: hLL1 (Milatuzumab,)—Berkova Z., et al  Expert Opin Investig Drugs.  2010 January; 19(1):141-9)
   For example, see US20040115193 SEQ ID NOs: 19, 20, 21, 22, 23 and 24
 
Genmab: HuMax-CD74 (see website)
 
(75) Claudins—CLs (Claudins)
 
Cross-References
 
Offner S., et al  Cancer Immunol Immunother.  2005 May; 54(5):431-45, Suzuki H., et al  Ann N Y Acad Sci.  2012 July; 1258:65-70)
 
In humans, 24 members of the family have been described—see literature reference.
 
(76) EGFR (Epidermal Growth Factor Receptor)
 
Nucleotide
 
Genbank accession no. NM_005228
 
Genbank version no. NM_005228.3 GI:41927737
 
Genbank record update date: Sep. 30, 2012 01:47 PM
 
Polypeptide
 
Genbank accession no. NP_005219
 
Genbank version no. NP_005219.2 GI:29725609
 
Genbank record update date: Sep. 30, 2012 01:47 PM
 
Cross-References
 
Dhomen N S., et al  Crit Rev Oncog.  2012; 17(1):31-50
 
Other Information
 
Official Symbol: EGFR
 
Other Aliases: ERBB, ERBB1, HER1, PIG61, mENA
 
Other Designations: avian erythroblastic leukemia viral (v-erb-b) oncogene homolog; cell  growth inhibiting protein  40; cell proliferation-inducing protein 61; proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1
 
Antibodies
 
BMS: Cetuximab (Erbitux)—Broadbridge V T., et al  Expert Rev Anticancer Ther.  2012 May; 12(5):555-65.
   For example, see U.S. Pat. No. 6,217,866—ATTC deposit No. 9764.
 
Amgen: Panitumumab (Vectibix)—Argiles G., et al  Future Oncol.  2012 April; 8(4):373-89
   For example, see U.S. Pat. No. 6,235,883 SEQ ID NOs: 23-38.       
 Genmab: Zalutumumab—Rivera F., et al  Expert Opin Biol Ther.  2009 May; 9(5):667-74. 
 YM Biosciences: Nimotuzumab—Ramakrishnan M S., et al MAbs. 2009 January-February; 1(1):41-8. 
 
   
 
 
 For example, see U.S. Pat. No. 5,891,996 SEQ ID NOs: 27-34.
 
(77) Her3 (ErbB3)—ERBB3 (v-Erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog 3 (Avian))
 
Nucleotide
 
Genbank accession no. M34309
 
Genbank version no. M34309.1 G1:183990
 
Genbank record update date: Jun. 23, 2010 08:47 PM
 
Polypeptide
 
Genbank accession no. AAA35979
 
Genbank version no. AAA35979.1 G1:306841
 
Genbank record update date: Jun. 23, 2010 08:47 PM
 
Cross-References
 
Plowman, G. D., et al.,  Proc. Natl. Acad. Sci. U.S.A.  87 (13), 4905-4909 (1990)
 
Other Information
 
Official Symbol: ERBB3
 
Other Aliases: ErbB-3, HER3, LCCS2, MDA-BF-1, c-erbB-3, c-erbB3, erbB3-S, p180-ErbB3, p45-sErbB3, p85-sErbB3
 
Other Designations: proto-oncogene-like protein c-ErbB-3; receptor tyrosine-protein kinase erbB-3; tyrosine kinase-type cell surface receptor HER3
 
Antibodies
 
Merimack Pharma: MM-121 (Schoeberl B., et al Cancer Res. 2010 Mar. 15; 70(6):2485-2494)
 
 For example, see US2011028129 SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7 and 8.
 
(78) RON—MST1R (Macrophage Stimulating 1 Receptor (c-Met-Related Tyrosine Kinase))
 
Nucleotide
 
Genbank accession no. X70040
 
Genbank version no. X70040.1 G1:36109
 
Genbank record update date: Feb. 2, 2011 10:17 PM
 
Polypeptide
 
Genbank accession no. CCA49634
 
Genbank version no. CCA49634.1 G1:36110
 
Genbank record update date: Feb. 2, 2011 10:17 PM
 
Cross-References
 
Ronsin C., et al  Oncogene  8 (5), 1195-1202 (1993)
 
Other Information
 
Official Symbol: MST1R
 
Other Aliases: CD136, CDw136, PTK8, RON
 
Other Designations: MSP receptor; MST1R variant RON30; MST1R variant RON62; PTK8  protein tyrosine kinase  8; RON variant E2E3; c-met-related tyrosine kinase; macrophage-stimulating protein receptor; p185-Ron; soluble RON variant 1; soluble RON variant 2;  soluble RON variant  3;  soluble RON variant  4
 
(79) EPHA2 (EPH Receptor A2)
 
Nucleotide
 
Genbank accession no. BC037166
 
Genbank version no. BC037166.2 G1:33879863
 
Genbank record update date: Mar. 6, 2012 01:59 PM
 
Polypeptide
 
Genbank accession no. AAH37166
 
Genbank version no. AAH37166.1 G1:22713539
 
Genbank record update date: Mar. 6, 2012 01:59 PM
 
Cross-References
 
Strausberg R. L., et al  Proc. Natl. Acad. Sci. U.S.A.  99 (26), 16899-16903 (2002)
 
Other Information
 
Official Symbol: EPHA2
 
Other Aliases: ARCC2, CTPA, CTPP1, ECK
 
Other Designations: ephrin type-A receptor 2; epithelial cell receptor protein tyrosine kinase; soluble EPHA2 variant 1; tyrosine-protein kinase receptor ECK
 
Antibodies
 
Medimmune: 1C1 (Lee J W., et al  Clin Cancer Res.  2010 May 1; 16(9):2562-2570)
 
 For example, see US20090304721A1 FIGS. 7 and 8.
 
(80) CD20—MS4A1 (Membrane-Spanning 4-Domains, Subfamily a, Member 1)
 
Nucleotide
 
Genbank accession no. M27394
 
Genbank version no. M27394.1 G1:179307
 
Genbank record update date: Nov. 30, 2009 11:16 AM
 
Polypeptide
 
Genbank accession no. AAA35581
 
Genbank version no. AAA35581.1 G1:179308
 
Genbank record update date: Nov. 30, 2009 11:16 AM
 
Cross-References
 
Tedder T. F., et al  Proc. Natl. Acad. Sci. U.S.A.  85 (1), 208-212 (1988)
 
Other Information
 
Official Symbol: MS4A1
 
Other Aliases: B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7
 
Other Designations: B-lymphocyte antigen CD20; B-lymphocyte cell-surface antigen B1; CD20 antigen; CD20 receptor; leukocyte surface antigen Leu-16
 
Antibodies
 
Genentech/Roche: Rituximab—Abdulla N E., et al  BioDrugs.  2012 Apr. 1; 26(2):71-82.
 
 For example, see U.S. Pat. No. 5,736,137, ATCC deposit No. HB-69119.
 
GSK/Genmab: Ofatumumab—Nightingale G., et al Ann Pharmacother. 2011 October; 45(10):1248-55.
 
 For example, see US20090169550A1 SEQ ID NOs: 2, 4 and 5.
 
Immunomedics: Veltuzumab—Goldenberg DM., et al  Leuk Lymphoma.  2010 May; 51(5):747-55.
 
 For example, see U.S. Pat. No. 7,919,273B2 SEQ ID NOs: 1, 2, 3, 4, 5 and 6.
 
(81) Tenascin C— TNC (Tenascin C)
 
Nucleotide
 
Genbank accession no. NM_002160
 
Genbank version no. NM_002160.3 G1:340745336
 
Genbank record update date: Sep. 23, 2012 02:33 PM
 
Polypeptide
 
Genbank accession no. NP_002151
 
Genbank version no. NP_002151.2 G1:153946395
 
Genbank record update date: Sep. 23, 2012 02:33 PM
 
Cross-References
 
Nies D. E., et al J. Biol. Chem. 266 (5), 2818-2823 (1991); Siri A., et al Nucleic Acids Res. 19 (3), 525-531 (1991)
 
Other Information
 
Official Symbol: TNC
 
Other Aliases: 150-225, GMEM, GP, HXB, JI, TN, TN-C
 
Other Designations: GP 150-225; cytotactin; glioma-associated-extracellular matrix antigen; hexabrachion (tenascin); myotendinous antigen; neuronectin; tenascin; tenascin-C isoform 14/AD1/16
 
Antibodies
 
Philogen: G11 (von Lukowicz T., et al  J Nuci Med.  2007 April; 48(4):582-7) and F16 (Pedretti M., et al Lung Cancer. 2009 April; 64(1):28-33)
 
 For example, see U.S. Pat. No. 7,968,685 SEQ ID NOs: 29, 35, 45 and 47.
 
(82) FAP (Fibroblast Activation Protein, Alpha)
 
Nucleotide
 
Genbank accession no. U09278
 
Genbank version no. U09278.1 G1:1888315
 
Genbank record update date: Jun. 23, 2010 09:22 AM
 
Polypeptide
 
Genbank accession no. AAB49652
 
Genbank version no. AAB49652.1 G1:1888316
 
Genbank record update date: Jun. 23, 2010 09:22 AM
 
Cross-References
 
Scanlan, M. J., et al  Proc. Natl. Acad. Sci. U.S.A.  91 (12), 5657-5661 (1994)
 
Other Information
 
Official Symbol: FAP
 
Other Aliases: DPPIV, FAPA
 
Other Designations: 170 kDa melanoma membrane-bound gelatinase; integral membrane serine protease; seprase
 
(83) DKK-1 (Dickkopf 1 Homolog ( Xenopus laevis )
 
Nucleotide
 
Genbank accession no. NM_012242
 
Genbank version no. NM_012242.2 G1:61676924
 
Genbank record update date: Sep. 30, 2012 01:48 PM
 
Polypeptide
 
Genbank accession no. NP_036374
 
Genbank version no. NP_036374.1 G1:7110719
 
Genbank record update date: Sep. 30, 2012 01:48 PM
 
Cross-References
 
Fedi P. et al  J. Biol. Chem.  274 (27), 19465-19472 (1999)
 
Other Information
 
Official Symbol: DKK1
 
Other Aliases: UNQ492/PRO1008, DKK-1, SK
 
Other Designations: dickkopf related protein-1; dickkopf-1 like; dickkopf-like protein 1; dickkopf-related protein 1; hDkk-1
 
Antibodies
 
Novartis: BHQ880 (Fulciniti M., et al  Blood.  2009 Jul. 9; 114(2):371-379)
 
 For example, see US20120052070A1 SEQ ID NOs: 100 and 108.
 
(84) Cd52 (Cd52 Molecule)
 
Nucleotide
 
Genbank accession no. NM_001803
 
Genbank version no. NM_001803.2 G1:68342029
 
Genbank record update date: Sep. 30, 2012 01:48 PM
 
Polypeptide
 
Genbank accession no. NP_001794
 
Genbank version no. NP_001794.2 G1:68342030
 
Genbank record update date: Sep. 30, 2012 01:48 PM
 
Cross-References
 
Xia M. Q., et al  Eur. J. Immunol.  21 (7), 1677-1684 (1991)
 
Other Information
 
Official Symbol: CD52
 
Other Aliases: CDW52
 
Other Designations: CAMPATH-1 antigen; CD52 antigen (CAMPATH-1 antigen); CDW52 antigen (CAMPATH-1 antigen); cambridge pathology 1 antigen; epididymal secretory protein E5; he5; human epididymis-specific protein 5
 
Antibodies
 
Alemtuzumab (Campath)—Skoetz N., et al  Cochrane Database Syst Rev.  2012 Feb. 15; 2:CD008078.
 
 For example, see Drugbank Acc. No. DB00087 (BIOD00109, BTD00109)
 
(85) CS1—SLAMF7 (SLAM Family Member 7)
 
Nucleotide
 
Genbank accession no. NM_021181
 
Genbank version no. NM_021181.3 GI:1993571
 
Genbank record update date: Jun. 29, 2012 11:24 AM
 
Polypeptide
 
Genbank accession no. NP_067004
 
Genbank version no. NP_067004.3 GI:19923572
 
Genbank record update date: Jun. 29, 2012 11:24 AM
 
Cross-References
 
Boles K. S., et al  Immunogenetics  52 (3-4), 302-307 (2001)
 
Other Information
 
Official Symbol: SLAMF7
 
Other Aliases: UNQ576/PRO1138, 19A, CD319, CRACC, CS1
 
Other Designations: 19A24 protein; CD2 subset 1; CD2-like receptor activating cytotoxic cells; CD2-like receptor-activating cytotoxic cells; membrane protein FOAP-12; novel LY9 (lymphocyte antigen 9) like protein; protein 19A
 
Antibodies
 
BMS: elotuzumab/HuLuc63 (Benson DM., et al  J Clin Oncol.  2012 Jun. 1; 30(16):2013-2015)
 
 For example, see US20110206701 SEQ ID NOs: 9, 10, 11, 12, 13, 14, 15 and 16.
 
(86) Endoglin—ENG (Endoglin)
 
Nucleotide
 
Genbank accession no. AF035753
 
Genbank version no. AF035753.1 GI:3452260
 
Genbank record update date: Mar. 10, 2010 06:36 PM
 
Polypeptide
 
Genbank accession no. AAC32802
 
Genbank version no. AAC32802.1 GI:3452261
 
Genbank record update date: Mar. 10, 2010 06:36 PM
 
Cross-References
 
Rius C., et al  Blood  92 (12), 4677-4690 (1998)
 
Official Symbol: ENG
 
Other Information
 
Other Aliases: RP11-228B15.2, CD105, END, HHT1, ORW, ORW1
 
Other Designations: CD105 antigen
 
(87) Annexin A1—ANXA1 (Annexin A1)
 
Nucleotide
 
Genbank accession no. X05908
 
Genbank version no. X05908.1 GI:34387
 
Genbank record update date: Feb. 2, 2011 10:02 AM
 
Polypeptide
 
Genbank accession no. CCA29338
 
Genbank version no. CCA29338.1 GI:34388
 
Genbank record update date: Feb. 2, 2011 10:02 AM
 
Cross-References
 
Wallner B. P., et al  Nature  320 (6057), 77-81 (1986)
 
Other Information
 
Official Symbol: ANXA1
 
Other Aliases: RP11-71A24.1, ANX1, LPC1
 
Other Designations: annexin I (lipocortin I); annexin-1; calpactin II; calpactin-2; chromobindin-9; lipocortin I; p35; phospholipase A2 inhibitory protein
 
(88) V-CAM (CD106)—VCAM1 (Vascular Cell Adhesion Molecule 1)
 
Nucleotide
 
Genbank accession no. M60335
 
Genbank version no. M60335.1 GI:340193
 
Genbank record update date: Jun. 23, 2010 08:56 AM
 
Polypeptide
 
Genbank accession no. AAA61269
 
Genbank version no. AAA61269.1 GI:340194
 
Genbank record update date: Jun. 23, 2010 08:56 AM
 
Cross-References
 
Hession C., et al  J. Biol. Chem.  266 (11), 6682-6685 (1991)
 
Other Information
 
Official Symbol VCAM1
 
Other Aliases: CD106, INCAM-100
 
Other Designations: CD106 antigen; vascular cell adhesion protein 1
 
 
 
 
 
 
 
 
 
 
   
 
 
 Antibody Sequences 
 
 
   
 
 
 
 Anti-Integrin αvβ6 
 
 
 RHAB6.2 
 
 
 QVQLVQSGSELKKPGASVKISCKASGFAFTDSYMHWVRQAPGQGLEWMGW 
 
 
 IDPENGDTEYAPKFQGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCTRGT 
 
 
 PTAVPNLRGDLQVLAQKVAGPYPFDYWGQGTLVTVSS 
 
 
   
 
 
 RHCB6.2 
 
 
 QVQLVQSGAEVKKPGASVKVSCKASGYTFIDSYMHWVRQAPGQRLEWMGW 
 
 
 IDPENGDTEYAPKFQGRVTITTDTSASTAYMELSSLRSEDTAVYYCARGT 
 
 
 PTAVPNLRGDLQVLAQKVAGPYPFDYWGQGTLVTVSS 
 
 
 RHF 
 
 
   
 
 
 QVQLVQSGAEVKKPGASVKVSCKASGFNFIDSYMHWVRQAPGQRLEWMGW 
 
 
 IDPENGDTEYAPKFQGRVTFTTDTSASTAYMELSSLRSEDTAVYYCNEGT 
 
 
 PTGPYYFDYWGQGTLVTVSS 
 
 
   
 
 
 RHFB6 
 
 
 QVQLVQSGAEVKKPGASVKVSCKASGFNFIDSYMHWVRQAPGQRLEWMGW 
 
 
 IDPENGDTEYAPKFQGRVTFTTDTSASTAYMELSSLRSEDTAVYYCNEGT 
 
 
 PTAVPNLRGDLQVLAQKVAGPYYFDYWGQGTLVTVSS 
 
 
   
 
 
 RHAY100bP 
 
 
 QVQLVQSGSELKKPGASVKISCKASGFAFTDSYMHWVRQAPGQGLEWMGW 
 
 
 IDPENGDTEYAPKFQGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCTRGT 
 
 
 PTGPYPFDYWGQGTLVTVSS 
 
 
   
 
 
 RKF 
 
 
 ENVLTQSPGTLSLSPGERATLSCSASSSVSYMHWFQQKPGQAPRLLIYST 
 
 
 SNLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQRSSYPLTFGGG 
 
 
 TKVEIK 
 
 
   
 
 
 RKFL36L50 
 
 
 ENVLTQSPGTLSLSPGERATLSCSASSSVSYMHWLQQKPGQAPRLLIYLT 
 
 
 SNLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQRSSYPLTFGGG 
 
 
 TKVEIKRKC 
 
 
   
 
 
 RKC 
 
 
 EIVLTQSPGTLSLSPGERATLSCSASSSVSYMHWFQQKPGQAPRLLIYST 
 
 
 SNLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQRSSYPLTFGGG 
 
 
 TKVEIK 
 
 
   
 
 
 Anti-CD33 
 
 
 CD33 Hum195 VH 
 
 
 QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYNMHWVRQAPGQGLEWIGY 
 
 
 IYPYNGGTGYNQKFKSKATITADESTNTAYMELSSLRSEDTAVYYCARGR 
 
 
 PAMDYWGQGTLVTVSS 
 
 
   
 
 
 CD33 Hum195 VK 
 
 
 DIQMTQSPSSLSASVGDRVTITCRASESVDNYGISFMNWFQQKPGKAPKL 
 
 
 LIYAASNQGSGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQSKEVPW 
 
 
 TFGQGTKVEIK 
 
 
   
 
 
 Anti-CD19 
 
 
 CD19 B4 resurfaced VH 
 
 
 QVQLVQPGAEVVKPGASVKLSCKTSGYTFTSNWMHWVKQRPGQGLEWIGE 
 
 
 IDPSDSYTNYNQNFKGKAKLTVDKSTSTAYMEVSSLRSDDTAVYYCARGS 
 
 
 NPYYYAMDYWGQGTSVTVSS 
 
 
   
 
 
 CD19 B4 resurfaced VK 
 
 
 EIVLTQSPAIMSASPGERVTMTCSASSGVNYMHWYQQKPGTSPRRWIYDT 
 
 
 SKLASGVPARFSGSGSGTSYSLTISSMEPEDAATYYCHQRGSYTFGGGTK 
 
 
 LEIK 
 
 
   
 
 
 Anti-Her2 
 
 
 Herceptin VH chain 
 
 
 EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVAR 
 
 
 IYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWG 
 
 
 GDGFYAMDYWGQGTLVTVSS 
 
 
   
 
 
 Herceptin VL chain 
 
 
 DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYS 
 
 
 ASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQ 
 
 
 GTKVEIK 
 
 
   
 
 
 Anti-CD25 
 
 
 Simulect VK (also known as Basiliximab) 
 
 
 QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDT 
 
 
 SKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTK 
 
 
 LEIK 
 
 
   
 
 
 Simulect VH 
 
 
 QLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIY 
 
 
 PGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGY 
 
 
 YFDFWGQGTTLTVSS 
 
 
   
 
 
 Anti-PSMA 
 
 
 Deimmunised VH ′1 
 
 
 EVQLVQSGPEVKKPGATVKISCKTSGYTFTEYTIHWVKQAPGKGLEWIGN 
 
 
 INPNNGGTTYNQKFEDKATLTVDKSTDTAYMELSSLRSEDTAVYYCAAGW 
 
 
 NFDYWGQGTLLTVSS 
 
 
   
 
 
 Deimmunised VK ′1 
 
 
 DIQMTQSPSSLSTSVGDRVTLTCKASQDVGTAVDWYQQKPGPSPKLLIYW 
 
 
 ASTRHTGIPSRFSGSGSGTDFTLTISSLQPEDFADYYCQQYNSYPLTFGP 
 
 
 GTKVDIK 
 
 
   
 
 
 Deimmunised VH1 ′5 
 
 
 EVKLVESGGGLVQPGGSMKLSCVASGFTFSNYWMNWVRQAPGKGLEWVAE 
 
 
 IRSQSNNFATHYAESVKGRVTISRDDSKSIVYLQMNNLRAEDTGVYYCTR 
 
 
 RWNNFWGQGTTVTVSS 
 
 
   
 
 
 Deimmunised VH2 ′5 
 
 
 EVKLVESGGGLVQPGGSLKLSCVASGFTFSNYWMNWVRQAPGKGLEWVAE 
 
 
 IRSQSNNFATHYAESVKGRVTISRDDSKSIVYLQMNNLRAEDTAVYYCTR 
 
 
 RWNNFWGQGTTVTVSS 
 
 
   
 
 
 Deimmunised VH3 ′5 
 
 
 EVQLVESGGGLVQPGGSLKLSCVASGFTFSNYWMNWVRQAPGKGLEWVAE 
 
 
 IRSQSNNFATHYAESVKGRVTISRDDSKSIVYLQMNNLRAEDTAVYYCTR 
 
 
 RWNNFWGQGTTVTVSS 
 
 
   
 
 
 Deimmunised VH4 ′5 
 
 
 EVQLVESGGGLVQPGGSLKLSCVASGFTFSNYWMNWVRQAPGKGLEWVAE 
 
 
 IRSQSNNFATHYAESVKGRFTISRDDSKSIVYLQMNNLRAEDTAVYYCTR 
 
 
 RWNNFWGQGTTVTVSS 
 
 
   
 
 
 Deimmunised VK1 ′5 
 
 
 NIVMTQFPSSMSASVGDRVTITCKASENVGTYVSWYQQKPDQSPKMLIYG 
 
 
 ASNRFTGVPDRFTGSGSATDFTLTISSLQTEDLADYYCGQSYTFPYTFGQ 
 
 
 GTKLEMK 
 
 
   
 
 
 Deimmunised VK2 ′5 
 
 
 NIVMTQFPSSMSASVGDRVTITCKASENVGTYVSWYQQKPDQSPKMLIYG 
 
 
 ASNRFTGVPDRFSGSGSGTDFTLTISSLQAEDLADYYCGQSYTFPYTFGQ 
 
 
 GTKLEIK 
 
 
   
 
 
 Deimmunised VK3 ′5 
 
 
 NIQMTQFPSAMSASVGDRVTITCKASENVGTYVSWYQQKPDQSPKMLIYG 
 
 
 ASNRFTGVPDRFSGSGSGTDFTLTISSLQAEDLADYYCGQSYTFPYTFGQ 
 
 
 GTKLEIK 
 
 
   
 
 
 Deimmunised VK4 ′5 
 
 
 NIQMTQFPSAMSASVGDRVTITCKASENVGTYVSWYQQKPDQSPKMLIYG 
 
 
 ASNRFTGVPDRFSGSGSGTDFTLTISSLQAEDEADYYCGQSYTFPYTFGQ 
 
 
 GTKLEIK 
 
 
   
 
 
 Deimmunised VK DI ′5 
 
 
 NIVMTQFPKSMSASAGERMTLTCKASENVGTYVSWYQQKPTQSPKMLIYG 
 
 
 ASNRFTGVPDRFSGSGSGTDFILTISSVQAEDLVDYYCGQSYTFPYTFGG 
 
 
 GTKLEMK 
 
 
   
 
 
 Deimmunised VH DI ′5 
 
 
 EVKLEESGGGLVQPGGSMKISCVASGFTFSNYWMNWVRQSPEKGLEWVAE 
 
 
 IRSQSNNFATHYAESVKGRVIISRDDSKSSVYLQMNSLRAEDTAVYYCTR 
 
 
 RWNNFWGQGTTVTVSS 
 
 
   
 
 
 Humanised RHA ′5 
 
 
 EVQLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNWVRQASGKGLEWVGE 
 
 
 IRSQSNNFATHYAESVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCTR 
 
 
 RWNNFWGQGTTVTVSS 
 
 
   
 
 
 Humanised RHB ′5 
 
 
 EVKLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNWVRQASGKGLEWVAE 
 
 
 IRSQSNNFATHYAESVKGRVIISRDDSKNTVYLQMNSLRTEDTAVYYCTR 
 
 
 RWNNFWGQGTTVTVSS 
 
 
   
 
 
 Humanised RHC ′5 
 
 
 EVQLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNWVRQASGKGLEWVAE 
 
 
 IRSQSNNFATHYAESVKGRVIISRDDSKNTVYLQMNSLRTEDTAVYYCTR 
 
 
 RWNNFWGQGTTVTVSS 
 
 
   
 
 
 Humanised RHD ′5 
 
 
 EVKLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNWVRQASGKGLEWVGE 
 
 
 IRSQSNNFATHYAESVKGRVIISRDDSKNTVYLQMNSLRTEDTAVYYCTR 
 
 
 RWNNFWGQGTTVTVSS 
 
 
   
 
 
 Humanised RHE ′5 
 
 
 EVKLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNWVRQASGKGLEWVAE 
 
 
 IRSQSNNFATHYAESVKGRFTISRDDSKNTVYLQMNSLRTEDTAVYYCTR 
 
 
 RWNNFWGQGTTVTVSS 
 
 
   
 
 
 Humanised RHF ′5 
 
 
 EVKLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNWVRQASGKGLEWVAE 
 
 
 IRSQSNNFATHYAESVKGRVIISRDDSKNTAYLQMNSLRTEDTAVYYCTR 
 
 
 RWNNFWGQGTTVTVSS 
 
 
   
 
 
 Humanised RHG ′5 
 
 
 EVKLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNWVRQASGKGLEWVAE 
 
 
 IRSQSNNFATHYAESVKGRVIISRDDSKNTAYLQMNSLRTEDTAVYYCTR 
 
 
 RWNNFWGQGTTVTVSS 
 
 
   
 
 
 Humanised RKA ′5 
 
 
 DIQMTQSPSSVSASVGDRVTITCKASENVGTYVSWYQQKPGTAPKLLIYG 
 
 
 ASNRFTGVPSRFSGSGSATDFTLTINNLQPEDFATYYCGQSYTFPYTFGQ 
 
 
 GTKVEIK 
 
 
   
 
 
 Humanised RKB ′5 
 
 
 DIQMTQSPSSVSASVGDRVTITCKASENVGTYVSWYQQKPGTAPKLLIYG 
 
 
 ASNRFTGVPSRFSGSGSATDFTLTINNLQPEDFATYYCGQSYTFPYTFGQ 
 
 
 GTKVEIK 
 
 
   
 
 
 Humanised RKC ′5 
 
 
 DIQMTQSPSSVSASVGDRVTITCKASENVGTYVSWYQQKPGTAPKMLIYG 
 
 
 ASNRFTGVPSRFSGSGSATDFTLTINNLQPEDFATYYCGQSYTFPYTFGQ 
 
 
 GTKVEIK 
 
 
   
 
 
 Humanised RKD ′5 
 
 
 DIQMTQSPSSVSASVGDRVTITCKASENVGTYVSWYQQKPGTAPKMLIYG 
 
 
 ASNRFTGVPSRFSGSGSATDFTLTINNLQPEDFATYYCGQSYTFPYTFGQ 
 
 
 GTKVEIK 
 
 
   
 
 
 Humanised RKE ′5 
 
 
 NIVMTQSPSSVSASVGDRVTITCKASENVGTYVSWYQQKPGTAPKLLIYG 
 
 
 ASNRFTGVPDRFTGSGSATDFILTINNLQPEDFATYYCGQSYTFPYTFGQ 
 
 
 GTKVEIK 
 
 
   
 
 
 Humanised RKF ′5 
 
 
 NIVMTQSPSSVSASVGDRVTITCKASENVGTYVSWYQQKPGTAPKMLIYG 
 
 
 ASNRFTGVPSRFSGSGSATDFILTINNLQPEDFATYYCGQSYTFPYTFGQ 
 
 
 GTKVEIK 
 
 
   
 
 
 Humanised RKG ′5 
 
 
 NIVMTQSPSSVSASVGDRVTITCKASENVGTYVSWYQQKPGTAPKMLIYG 
 
 
 ASNRFTGVPDRFTGSGSATDFTLTINNLQPEDFATYYCGQSYTFPYTFGQ 
 
 
 GTKVEIK 
 
 
   
 
 
 
 
 
 The parent antibody may also be a fusion protein comprising an albumin-binding peptide (ABP) sequence (Dennis et al. (2002) “Albumin Binding As A General Strategy For Improving The Pharmacokinetics Of Proteins”  J Biol Chem.  277:35035-35043; WO 01/45746). Antibodies of the invention include fusion proteins with ABP sequences taught by: (i) Dennis et al (2002)  J Biol Chem.  277:35035-35043 at Tables III and IV, page 35038; (ii) US 2004/0001827 at [0076]; and (iii) WO 01/45746 at pages 12-13, and all of which are incorporated herein by reference. 
 In one embodiment, the antibody has been raised to target specific the tumour related antigen α v β 6 . 
 The cell binding agent may be labelled, for example to aid detection or purification of the agent either prior to incorporation as a conjugate, or as part of the conjugate. The label may be a biotin label. In another embodiment, the cell binding agent may be labelled with a radioisotope. 
 Connection of Linker Unit to Ligand Unit 
 The Ligand unit is connected to the Linker unit through a disulfide bond. 
 In one embodiment, the connection between the Ligand unit and the Drug Linker is formed between a thiol group of a cysteine residue of the Ligand unit and a maleimide group of the Drug Linker unit. 
 The cysteine residues of the Ligand unit may be available for reaction with the functional group of the Linker unit to form a connection. In other embodiments, for example where the Ligand unit is an antibody, the thiol groups of the antibody may participate in interchain disulfide bonds. These interchain bonds may be converted to free thiol groups by e.g. treatment of the antibody with DTT prior to reaction with the functional group of the Linker unit. 
 In some embodiments, the cysteine residue is an introduced into the heavy or light chain of an antibody. Positions for cysteine insertion by substitution in antibody heavy or light chains include those described in Published U.S. Application No. 2007-0092940 and International Patent Publication WO2008070593, which are incorporated herein. 
 Methods of Treatment 
 The compounds of the present invention may be used in a method of therapy. Also provided is a method of treatment, comprising administering to a subject in need of treatment a therapeutically-effective amount of a conjugate of formula I. The term “therapeutically effective amount” is an amount sufficient to show benefit to a patient. Such benefit may be at least amelioration of at least one symptom. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage, is within the responsibility of general practitioners and other medical doctors. 
 A conjugate may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated. Examples of treatments and therapies include, but are not limited to, chemotherapy (the administration of active agents, including, e.g. drugs; surgery; and radiation therapy. 
 Pharmaceutical compositions according to the present invention, and for use in accordance with the present invention, may comprise, in addition to the active ingredient, i.e. a conjugate of formula I, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, e.g. cutaneous, subcutaneous, or intravenous. 
 Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may comprise a solid carrier or an adjuvant. Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included. A capsule may comprise a solid carrier such a gelatin. 
 For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required. 
 The Conjugates can be used to treat proliferative disease and autoimmune disease. The term “proliferative disease” pertains to an unwanted or uncontrolled cellular proliferation of excessive or abnormal cells which is undesired, such as, neoplastic or hyperplastic growth, whether in vitro or in vivo. 
 Examples of proliferative conditions include, but are not limited to, benign, pre-malignant, and malignant cellular proliferation, including but not limited to, neoplasms and tumours (e.g., histocytoma, glioma, astrocyoma, osteoma), cancers (e.g. lung cancer, small cell lung cancer, gastrointestinal cancer, bowel cancer, colon cancer, breast carinoma, ovarian carcinoma, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreatic cancer, brain cancer, sarcoma, osteosarcoma, Kaposi's sarcoma, melanoma), leukemias, psoriasis, bone diseases, fibroproliferative disorders (e.g. of connective tissues), and atherosclerosis. Other cancers of interest include, but are not limited to, haematological; malignancies such as leukemias and lymphomas, such as non-Hodgkin lymphoma, and subtypes such as DLBCL, marginal zone, mantle zone, and follicular, Hodgkin lymphoma, AML, and other cancers of B or T cell origin. 
 Examples of autoimmune disease include the following: rheumatoid arthritis, autoimmune demyelinative diseases (e.g., multiple sclerosis, allergic encephalomyelitis), psoriatic arthritis, endocrine ophthalmopathy, uveoretinitis, systemic lupus erythematosus, myasthenia gravis, Graves' disease, glomerulonephritis, autoimmune hepatological disorder, inflammatory bowel disease (e.g., Crohn's disease), anaphylaxis, allergic reaction, Sjögren's syndrome, type I diabetes mellitus, primary biliary cirrhosis, Wegener's granulomatosis, fibromyalgia, polymyositis, dermatomyositis, multiple endocrine failure, Schmidt's syndrome, autoimmune uveitis, Addison's disease, adrenalitis, thyroiditis, Hashimoto's thyroiditis, autoimmune thyroid disease, pernicious anemia, gastric atrophy, chronic hepatitis, lupoid hepatitis, atherosclerosis, subacute cutaneous lupus erythematosus, hypoparathyroidism, Dressler's syndrome, autoimmune thrombocytopenia, idiopathic thrombocytopenic purpura, hemolytic anemia, pemphigus vulgaris, pemphigus, dermatitis herpetiformis, alopecia arcata, pemphigoid, scleroderma, progressive systemic sclerosis, CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia), male and female autoimmune infertility, ankylosing spondolytis, ulcerative colitis, mixed connective tissue disease, polyarteritis nedosa, systemic necrotizing vasculitis, atopic dermatitis, atopic rhinitis, Goodpasture's syndrome, Chagas' disease, sarcoidosis, rheumatic fever, asthma, recurrent abortion, anti-phospholipid syndrome, farmer's lung, erythema multiforme, post cardiotomy syndrome, Cushing's syndrome, autoimmune chronic active hepatitis, bird-fancier's lung, toxic epidermal necrolysis, Alport's syndrome, alveolitis, allergic alveolitis, fibrosing alveolitis, interstitial lung disease, erythema nodosum, pyoderma gangrenosum, transfusion reaction, Takayasu's arteritis, polymyalgia rheumatica, temporal arteritis, schistosomiasis, giant cell arteritis, ascariasis, aspergillosis, Sampter's syndrome, eczema, lymphomatoid granulomatosis, Behcet's disease, Caplan's syndrome, Kawasaki's disease, dengue, encephalomyelitis, endocarditis, endomyocardial fibrosis, endophthalmitis, erythema elevatum et diutinum, psoriasis, erythroblastosis fetalis, eosinophilic faciitis, Shulman's syndrome, Felty's syndrome, filariasis, cyclitis, chronic cyclitis, heterochronic cyclitis, Fuch's cyclitis, IgA nephropathy, Henoch-Schonlein purpura, graft versus host disease, transplantation rejection, cardiomyopathy, Eaton-Lambert syndrome, relapsing polychondritis, cryoglobulinemia, Waldenstrom's macroglobulemia, Evan's syndrome, and autoimmune gonadal failure. 
 In some embodiments, the autoimmune disease is a disorder of B lymphocytes (e.g., systemic lupus erythematosus, Goodpasture's syndrome, rheumatoid arthritis, and type I diabetes), Th1-lymphocytes (e.g., rheumatoid arthritis, multiple sclerosis, psoriasis, Sjögren's syndrome, Hashimoto's thyroiditis, Graves' disease, primary biliary cirrhosis, Wegener's granulomatosis, tuberculosis, or graft versus host disease), or Th2-lymphocytes (e.g., atopic dermatitis, systemic lupus erythematosus, atopic asthma, rhinoconjunctivitis, allergic rhinitis, Omenn's syndrome, systemic sclerosis, or chronic graft versus host disease). Generally, disorders involving dendritic cells involve disorders of Th1-lymphocytes or Th2-lymphocytes. In some embodiments, the autoimmunie disorder is a T cell-mediated immunological disorder. 
 In some embodiments, the amount of the Conjugate administered ranges from about 0.01 to about 10 mg/kg per dose. In some embodiments, the amount of the Conjugate administered ranges from about 0.01 to about 5 mg/kg per dose. In some embodiments, the amount of the Conjugate administered ranges from about 0.05 to about 5 mg/kg per dose. In some embodiments, the amount of the Conjugate administered ranges from about 0.1 to about 5 mg/kg per dose. In some embodiments, the amount of the Conjugate administered ranges from about 0.1 to about 4 mg/kg per dose. In some embodiments, the amount of the Conjugate administered ranges from about 0.05 to about 3 mg/kg per dose. In some embodiments, the amount of the Conjugate administered ranges from about 0.1 to about 3 mg/kg per dose. In some embodiments, the amount of the Conjugate administered ranges from about 0.1 to about 2 mg/kg per dose. 
 Drug Loading 
 The drug loading (p) is the average number of PBD drugs per cell binding agent, e.g. antibody. Where the compounds of the invention are bound to cysteines, drug loading may range from 1 to 8 drugs (D) per cell binding agent, i.e. where 1, 2, 3, 4, 5, 6, 7, and 8 drug moieties are covalently attached to the cell binding agent. Compositions of conjugates include collections of cell binding agents, e.g. antibodies, conjugated with a range of drugs, from 1 to 8. Where the compounds of the invention are bound to lysines, drug loading may range from 1 to 80 drugs (D) per cell binding agent, although an upper limit of 40, 20, 10 or 8 may be preferred. Compositions of conjugates include collections of cell binding agents, e.g. antibodies, conjugated with a range of drugs, from 1 to 80, 1 to 40, 1 to 20, 1 to 10 or 1 to 8. 
 The average number of drugs per antibody in preparations of ADC from conjugation reactions may be characterized by conventional means such as UV, reverse phase HPLC, HIC, mass spectroscopy, ELISA assay, and electrophoresis. The quantitative distribution of ADC in terms of p may also be determined. By ELISA, the averaged value of p in a particular preparation of ADC may be determined (Hamblett et al (2004) Clin. Cancer Res. 10:7063-7070; Sanderson et al (2005) Clin. Cancer Res. 11:843-852). However, the distribution of p (drug) values is not discernible by the antibody-antigen binding and detection limitation of ELISA. Also, ELISA assay for detection of antibody-drug conjugates does not determine where the drug moieties are attached to the antibody, such as the heavy chain or light chain fragments, or the particular amino acid residues. In some instances, separation, purification, and characterization of homogeneous ADC where p is a certain value from ADC with other drug loadings may be achieved by means such as reverse phase HPLC or electrophoresis. Such techniques are also applicable to other types of conjugates. 
 For some antibody-drug conjugates, p may be limited by the number of attachment sites on the antibody. For example, an antibody may have only one or several cysteine thiol groups, or may have only one or several sufficiently reactive thiol groups through which a linker may be attached. Higher drug loading, e.g. p>5, may cause aggregation, insolubility, toxicity, or loss of cellular permeability of certain antibody-drug conjugates. 
 Typically, fewer than the theoretical maximum of drug moieties are conjugated to an antibody during a conjugation reaction. An antibody may contain, for example, many lysine residues that do not react with the Drug Linker. Only the most reactive lysine groups may react with an amine-reactive linker reagent. Also, only the most reactive cysteine thiol groups may react with a thiol-reactive linker reagent. Generally, antibodies do not contain many, if any, free and reactive cysteine thiol groups which may be linked to a drug moiety. Most cysteine thiol residues in the antibodies of the compounds exist as disulfide bridges and must be reduced with a reducing agent such as dithiothreitol (DTT) or TCEP, under partial or total reducing conditions. The loading (drug/antibody ratio) of an ADC may be controlled in several different manners, including: (i) limiting the molar excess of Drug Linker relative to antibody, (ii) limiting the conjugation reaction time or temperature, and (iii) partial or limiting reductive conditions for cysteine thiol modification. 
 Certain antibodies have reducible interchain disulfides, i.e. cysteine bridges. Antibodies may be made reactive for conjugation with linker reagents by treatment with a reducing agent such as DTT (dithiothreitol). Each cysteine bridge will thus form, theoretically, two reactive thiol nucleophiles. Additional nucleophilic groups can be introduced into antibodies through the reaction of lysines with 2-iminothiolane (Traut's reagent) resulting in conversion of an amine into a thiol. Reactive thiol groups may be introduced into the antibody (or fragment thereof) by engineering one, two, three, four, or more cysteine residues (e.g., preparing mutant antibodies comprising one or more non-native cysteine amino acid residues). U.S. Pat. No. 7,521,541 teaches engineering antibodies by introduction of reactive cysteine amino acids. 
 Cysteine amino acids may be engineered at reactive sites in an antibody and which do not form intrachain or intermolecular disulfide linkages (Junutula, et al., 2008b Nature Biotech., 26(8):925-932; Dornan et al (2009) Blood 114(13):2721-2729; U.S. Pat. Nos. 7,521,541; 7,723,485; WO2009/052249). The engineered cysteine thiols may react with linker reagents or the drug-linker reagents of the present invention which have thiol-reactive, electrophilic groups such as maleimide or alpha-halo amides to form ADC with cysteine engineered antibodies and the PBD drug moieties. The location of the drug moiety can thus be designed, controlled, and known. The drug loading can be controlled since the engineered cysteine thiol groups typically react with thiol-reactive linker reagents or drug-linker reagents in high yield. Engineering an IgG antibody to introduce a cysteine amino acid by substitution at a single site on the heavy or light chain gives two new cysteines on the symmetrical antibody. A drug loading near 2 can be achieved with near homogeneity of the conjugation product ADC. 
 Where more than one nucleophilic or electrophilic group of the antibody reacts with a drug-linker intermediate, or linker reagent followed by drug moiety reagent, then the resulting product is a mixture of ADC compounds with a distribution of drug moieties attached to an antibody, e.g. 1, 2, 3, etc. Liquid chromatography methods such as polymeric reverse phase (PLRP) and hydrophobic interaction (HIC) may separate compounds in the mixture by drug loading value. Preparations of ADC with a single drug loading value (p) may be isolated, however, these single loading value ADCs may still be heterogeneous mixtures because the drug moieties may be attached, via the linker, at different sites on the antibody. 
 Thus the antibody-drug conjugate compositions of the invention include mixtures of antibody-drug conjugate compounds where the antibody has one or more PBD drug moieties and where the drug moieties may be attached to the antibody at various amino acid residues. 
 In one embodiment, the average number of dimer pyrrolobenzodiazepine groups per cell binding agent is in the range 1 to 20. In some embodiments the range is selected from 1 to 8, 2 to 8, 2 to 6, 2 to 4, and 4 to 8. 
 In some embodiments, there is one dimer pyrrolobenzodiazepine group per cell binding agent. 
 General Synthetic Routes 
 The synthesis of PBD compounds is extensively discussed in the following references, which discussions are incorporated herein by reference: 
 a) WO 00/12508 (pages 14 to 30); 
 b) WO 2005/023814 ( pages  3 to 10); 
 c) WO 2004/043963 ( pages  28 to 29); and 
 d) WO 2005/085251 ( pages  30 to 39). 
 Synthesis Route 
 The Drug Linker compound of the present invention may be synthesised according to the Examples. 
 Synthesis of Drug Conjugates 
 Conjugates can be prepared as previously described. Antibodies can be conjugated to the Drug Linker compound as described in Doronina et al., Nature Biotechnology, 2003, 21, 778-784). Briefly, antibodies (4-5 mg/mL) in PBS containing 50 mM sodium borate at pH 7.4 are reduced with tris(carboxyethyl)phosphine hydrochloride (TCEP) at 37° C. The progress of the reaction, which reduces interchain disulfides, is monitored by reaction with 5,5′-dithiobis(2-nitrobenzoic acid) and allowed to proceed until the desired level of thiols/mAb is achieved. The reduced antibody is then cooled to 0° C. and alkylated with 1.5 equivalents of maleimide drug-linker per antibody thiol. After 1 hour, the reaction is quenched by the addition of 5 equivalents of N-acetyl cysteine. Quenched drug-linker is removed by gel filtration over a PD-10 column. The ADC is then sterile-filtered through a 0.22 μm syringe filter. Protein concentration can be determined by spectral analysis at 280 nm and 329 nm, respectively, with correction for the contribution of drug absorbance at 280 nm. Size exclusion chromatography can be used to determine the extent of antibody aggregation, and RP-HPLC can be used to determine the levels of remaining NAC-quenched drug-linker. 
 Further Preferences 
 The following preferences may apply to all aspects of the invention as described above, or may relate to a single aspect. The preferences may be combined together in any combination. 
 In some embodiments, the C11 substituent may be in the following stereochemical arrangement relative to neighbouring groups: 
 
 
 
 
   
   
 
 
 
 In other embodiments, the C11 substituent may be in the following stereochemical arrangement relative to neighbouring groups: 
 
 
 
 
   
   
 
 
 
 EXAMPLES 
 Reaction progress was monitored by thin-layer chromatography (TLC) using  Merck Kieselgel  60 F254 silica gel, with fluorescent indicator on aluminium plates. Visualisation of TLC was achieved with UV light or iodine vapour unless otherwise stated. Flash chromatography was performed using  Merck Kieselgel  60 F254 silica gel. Extraction and chromatography solvents were bought and used without further purification from VWR, U.K. All chemicals were purchased from Aldrich. 
 Proton NMR chemical shift values were measured on the delta scale at 400 MHz using a Bruker AV400. The following abbreviations have been used: s, singlet; d, doublet; t, triplet; q, quartet; quin, quintet; m, multiplet; br, broad. Coupling constants are reported in Hz. Column chromatography was performed on an Isolera (Biotage) automated system using normal phase SNAP cartridges. 
 The LC/MS Conditions were as Follow: 
 LCMS data were obtained using a Shimadzu Nexera series LC/MS with a Shimadzu LCMS-2020 quadrupole MS, with Electrospray ionisation. Mobile phase A—0.1% formic acid in water. Mobile phase B—0.1% formic acid in acetonitrile. 
 Short run gradient: initial composition was 5% B held over 0.25 min, then increase from 5% B to 100% B over a 2 min period. The composition was held for 0.50 min at 100% B, then returned to 5% B in 0.05 minutes and hold there for 0.05 min. Total gradient run time equals 3 min. Flow rate 0.8 mL/min. Wavelength detection range: 190 to 800 nm. Oven temperature: 50° C. Column: Waters Acquity UPLC BEH Shield RP18 1.7 μm 2.1×50 mm. 
 Long run gradient: initial composition 5% B held over 1 min, then increase from 5% B to 100% B over a 9 min period. The composition was held for 2 min at 100% B, then returned to 5% B in 0.10 minutes and hold there for 3 min. Total gradient run time equals 15 min. 
 Flow rate 0.6 mL/min. Wavelength detection range: 190 to 800 nm. Oven temperature: 50° C. Column: ACE Excel 2 C18-AR, 2 μ, 3.0×100 mm. 
 Example 1 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 Compound 1 is compound 13 of WO 2014/057073. 
 (a) (S)-2-(4-aminophenyl)-8-(3-(((S)-2-(3-fluoro-4-methoxyphenyl)-7-methoxy-5,11-dioxo-10-((2-(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)propoxy)-7-methoxy-10-((2-(trimethylsilyl)ethoxy)methyl)-1,11a-dihydro-5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(1 OH)-dione (2) 
 Pd(PPh 3 ) 4 (21 mg, 0.018 mmol) was added to a stirred mixture of the aniline-triflate 1 (981.2 mg, 0.92 mmol), boronic ester (287.8 mg, 1.11 mmol) and Na 2 CO 3  (451 mg, 4.2 mmol) in a 2:1:1 mixture of toluene/MeOH/H 2 O (20 mL). The reaction mixture was allowed to stir at 30° C. under a nitrogen atmosphere for 2 hours after which time all of triflate 1 has reacted. The reaction mixture was then evaporated to dryness before the residue was taken up in CH 2 Cl 2  (50 mL) and washed with H 2 O (2×50 mL), brine (50 mL), dried (MgSO 4 ), filtered and evaporated under reduced pressure to provide the crude product. Purification by flash chromatography (gradient elution: 1:1 v/v Hexane/EtOAc to 100% EtOAc) afforded product 2 as a yellow foam (845.9 mg, 88%). LC/MS 2.01 min (ES+) m/z (relative intensity) 1036.45 ([M+H] + , 60%). 
 (b) (9H-fluoren-9-yl)methyl ((S)-1-(((S)-1-((4-((S)-8-(3-(((S)-2-(3-fluoro-4-methoxyphenyl)-7-methoxy-5,11-dioxo-10-((2-(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)propoxy)-7-methoxy-5,11-dioxo-10-((2-(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-2-yl)phenyl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (3) 
 To a solution of 2 (845.9 mg, 0.81 mmol) in dry CH 2 Cl 2  (25 mL) was added the protected peptide (368 g, 0.89 mmol) and EEDQ (222 mg, 0.89 mmol). The mixture was stirred at room temperature until completion (16 hours). The reaction mixture was then washed with H 2 O (2×25 mL), brine (25 mL), dried (MgSO 4 ), filtered and evaporated under reduced pressure to provide the crude product. Purification by flash chromatography (gradient elution: 100% CHCl 3  to 93/7 CHCl 3 /MeOH) afforded  product  3 as a yellow foam (987 mg, 84%). LC/MS 2.16 min (ES+) m/z (relative intensity) 1428.50 ([M+H] + , 5%); 1450.90 ([M+Na]) + , 50%). 
 (c) (9H-fluoren-9-yl)methyl ((S)-1-(((S)-1-((4-((S)-8-(3-(((S)-2-(3-fluoro-4-methoxyphenyl)-7-methoxy-5-oxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)propoxy)-7-methoxy-5-oxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-2-yl)phenyl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (4) 
 A solution of Super-Hydride® (1.75 mL, 1M in THF) was added dropwise to a solution of SEM-dilactam 3 (987 mg, 0.7 mmol) in dry THF (3 mL) at −78° C. under an argon atmosphere. The addition was completed over 5 minutes in order to maintain the internal temperature of the reaction mixture constant. After 40 minutes, an aliquot was quenched with water for LC/MS analysis, which revealed that the reaction was complete. Water (20 mL) was added to the reaction mixture and the cold bath was removed. The organic layer was extracted with CH 2 Cl 2  (3×50 mL) and the combined organics were washed with brine (100 mL), dried with MgSO 4 , filtered and the solvent removed by rotary evaporation under reduced pressure. The crude product was dissolved in MeOH (9 mL), CH 2 Cl 2  (3 mL), water (1 mL) and enough silica gel to form a thick stirring suspension. After 5 days, the suspension was filtered through a sintered funnel and washed with CH 2 Cl 2 /MeOH (9:1) (100 mL) until the elution of the product was complete. The organic layer was washed with brine (2×50 mL), dried with MgSO 4 , filtered and the solvent removed by rotary evaporation under reduced pressure. Purification by silica gel column chromatography (isolera, CHCl 3 /MeOH 98:2 to 80:20) afforded  product  4 as a yellow solid (563 mg, 71%). LC/MS 1.73 min (ES+) m/z (relative intensity) 1336.35 ([M+H] + , 10%). 
 (d) (S)-2-amino-N—((S)-1-((4-((S)-8-(3-(((S)-2-(3-fluoro-4-methoxyphenyl)-7-methoxy-5-oxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)propoxy)-7-methoxy-5-oxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-2-yl)phenyl)amino)-1-oxopropan-2-yl)-3-methylbutanamide (5) 
 Excess piperidine was added (0.2 mL) to a solution of PBD 4 (563 mg, 0.49 mmol) in DMF (3 mL). The mixture was allowed to stir at room temperature for 20 min, at which point the reaction had gone to completion (as monitored by LC/MS). The reaction mixture was diluted with CH 2 Cl 2  (50 mL) and the organic phase was washed with H 2 O (2×50 mL) until complete piperidine removal. The organic phase was dried over MgSO 4 , filtered and excess solvent removed by rotary evaporation under reduced pressure to afford crude product 5 which was used as such in the next step. LC/MS 1.15 min (ES+) m/z (relative intensity) 914.40 ([M+H] + , 10%). 
 (e) 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N—((S)-1-(((S)-1-((4-((S)-8-(3-(((S)-2-(3-fluoro-4-methoxyphenyl)-7-methoxy-5-oxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)propoxy)-7-methoxy-5-oxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-2-yl)phenyl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)hexanamide (6) 
 EDCl hydrochloride (94 mg, 0.49 mmol) and 6-maleimidohexanoic acid (104 mg, 0.49 mmol) were added to a solution of crude 5 in dry CH 2 Cl 2  (15 mL) under an argon atmosphere. Stirring was maintained until the reaction was complete (4h). The reaction was diluted with CH 2 Cl 2  (50 mL) and the organic phase was washed with H 2 O (2×50 mL) and brine before being dried over MgSO 4 , filtered and excess solvent removed by rotary evaporation under reduced pressure by rotary evaporation under reduced pressure. The product was purified by silica gel chromatography column (100% CHCl 3  to 95:5 CHCl 3 /MeOH) affording 6 (82.9 mg, 15%). LC/MS 1.50 min (ES+) m/z (relative intensity) 1107.80 ([M+H] + , 80%). LC/MS (long run) 6.90 min (ES+) m/z (relative intensity) 1107.80 ([M+H] + , 50%). 
 Example 2—Conjugation 
 Conjugate Tratuzumab-6 
 A 50 mM solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP) in phosphate-buffered saline pH 7.4 (PBS) was added (50 molar equivalent/antibody, 30 micromoles, 600 μL) to a 21 mL solution of antibody, Trastuzumab, (90 mg, 600 nanomoles) in reduction buffer containing PBS and 1 mM ethylenediaminetetraacetic acid (EDTA) and a final antibody concentration of 4.35 mg/mL. The reduction mixture was heated at +37° C. for 3 hours (or until full reduction is observed by UHPLC) in an incubator with gentle (135 rpm) shaking. After cooling down to room temperature, the reduced antibody was buffer exchanged, via spin filter centrifugation, into a reoxidation buffer containing PBS pH 7.4 and 1 mM EDTA to remove all the excess reducing agent. A 50 mM solution of dehydroascorbic acid (DHAA, 13 molar equivalent/antibody, 7.8 micromoles, 156 μL) in DMSO was added and the reoxidation mixture was allowed to react for 16 hours at room temperature with gentle (<150 rpm) shaking at an antibody concentration of 2 mg/mL (or more DHAA added and reaction left for longer until full reoxidation of the cysteine thiols to reform the inter-chain cysteine disulfides is observed by UHPLC). The reoxidation mixture was then sterile-filtered and diluted in a conjugation buffer containing PBS pH 7.4, 1 mM EDTA for a final antibody concentration of 1.0-1.5 mg/mL.  Compound  6 was added as a DMSO solution (20 molar equivalent/antibody, 2.0 micromole, in 1.0 mL DMSO) to 9 mL of this reoxidised antibody solution (15 mg, 100 nanomoles) for a 10% (v/v) DMSO concentration, followed by addition of propylene glycol (˜15% final v/v) after 10-15 minutes to solubilise the payload. The solution was mixed for 5 hours at room temperature, after which the conjugation was quenched by addition of N-acetyl-L-cysteine (6 micromoles, 60 L at 100 mM). The conjugation mixture was purified by spin filtration using a 15 mL Amicon Ultracell 50 kDa MWCO spin filter, then further purified by tangential flow filtration (TFF) to >50 diavolumes using a Spectrum Labs KrosFlo Research IIi system with a 30 kDa MWCO, 115 cm 2  surface area hollow fibre filter module at 50 mL/min in PBS with a transmembrane pressure (TMP) of 0.5-1.0 bar, and sterile-filtered and analysed. 
 UHPLC analysis on a Shimadzu Prominence system using a Phenomenex Aeris 3.6u XB-C18 150 mm×2.1 mm column eluting with a gradient of water and acetonitrile on a reduced sample of Conjugate Tratusumab-6 at 280 nm and 330 nm ( Compound  6 specific) shows unconjugated light chains and a mixture of unconjugated heavy chains and heavy chains attached to a single molecule of  Compound  6, consistent with a drug-per-antibody ratio (DAR) of 1.67 molecules of  Compound  6 per antibody. 
 UHPLC analysis on a Shimadzu Prominence system using a Tosoh Bioscience TSKgel G3000SWXL 5 μm 7.8×300 mm column (with a 7 μm 6.0×40 mm guard column) eluting with sterile-filtered SEC buffer containing 200 mM potassium phosphate pH 6.95, 250 mM potassium chloride and 10% isopropanol (v/v) on a sample of Conjugate Tratusumab-6 at 280 nm shows a monomer purity of 96%. UHPLC SEC analysis gives a concentration of final Conjugate Tratusumab-6 at 0.44 mg/mL in 19.0 mL, obtained mass of Conjugate Tratusumab-6 is 8.3 mg (56% yield). 
 Example 3—In Vitro Testing 
 Medium from sub-confluent (80-90% confluency) cell culture in a T75 flask was aspirated and the flask rinsed with PBS (about 20 ml) and emptied. Trypsin-EDTA (5 ml) was added, the flask returned to the 37° C. gassed incubator for up to about 5 minutes, then rapped sharply to dislodge and dissociate cells from the plastic. The cell suspension was transferred to a sterile 50 ml screw-top centrifuge tube, diluted with growth medium to a final volume of 15 ml, then centrifuged (400 g for 5 min). The supernatant was aspirated and the pellet re-suspended in 10 ml culture medium. Repeated pipetting may be necessary to produce monodisperse cell suspensions. The cell concentration and viability are measured of trypan blue cell stained cells, using a haemocytometer. Cells were diluted to 2×10 5 /ml, dispensed (50 μl/well) into 96 well flat bottom plates and incubated overnight before use. A stock solution (1 ml) of antibody drug conjugate (ADC) (20 μg/ml) was made by dilution of filter-sterilised ADC into cell culture medium. A set of 8×10-fold dilutions of stock ADC were made in a 24 well plate by serial transfer of 100 μl onto 900 μl of cell culture medium. 
 ADC dilution was dispensed (50 μl/well) into 4 replicate wells of the 96-well plate, containing 50 μl cell suspension seeded the previous day. Control wells received 50 μl cell culture medium. 
 The 96-well plate containing cells and ADCs was incubated at 37° C. in a CO 2 -gassed incubator for the exposure time. 
 At the end of the incubation period, cell viability was measured by MTS assay. MTS (Promega) was dispensed (20 μl per well) into each well and incubated for 4 hours at 37° C. in the CO 2 -gassed incubator. Well absorbance was measured at 490 nm. Percentage cell survival was calculated from the mean absorbance in the 4 ADC-treated wells compared to the mean absorbance in the 4 control untreated wells (100%). IC 50  was determined from the doses-response data using GraphPad Prism using the non-linear curve fit algorithm: sigmoidal, 4PL X is log(concentration). 
 
 
 
 
 
 
 
   
 
 
   
   
 ADC 
 Cell growth 
 
 
 Cell Line 
 Description 
 Exposure 
 medium 
 
 
   
 
 
 
 MDA MB 468 
 HER2 negative, 
 4 days 
 RPMI 1640 with 
 
 
   
 Breast carcinoma 
   
 glutamax, 10% FBS 
 
 
   SKBR3     Breast carcinoma     
 4 days 
 McCoys with 
 
 
   
   
   
 Glutamax, 10% FBS 
 
 
 BT474 
 Breast carcinoma 
 5 days 
 DMEM with 
 
 
   
   
   
 glutamax, 10% FBS 
 
 
 NCIN87 
 Gastric carcinoma 
 7 days 
 RPMI 1640 with 
 
 
   
   
   
 glutamax, 10% FBS 
 
 
   
 
 
 
 
 
 
 
 
 
 
   
   
 
 
   
 IC 50  (μg/ml) in: 
 
 
 
 
 ADC 
 MDMA MB 468 
 BT474 
 NCI-N87 
 SKBR3 
 
 
   
 
 
 trastuzumab-6 
 ~100 
 1.935 
 0.024 
 0.085 
 
 
   
 
 
 
 
 
 Example 4—Xenograft Testing 
 Mice 
 Female severe combined immune-deficient mice (Fox Chase SCID®, C.B-17/Icr-Prkdcscid, Charles River) were ten weeks old with a body weight (BW) range of 16.2 to 21.9 grams on Day 1 of the study. The animals were fed ad libitum water (reverse osmosis, 1 ppm Cl), and NIH 31 Modified and Irradiated Lab Diet® consisting of 18.0% crude protein, 5.0% crude fat, and 5.0% crude fibre. The mice were housed on irradiated Enricho'Cobs™ Laboratory Animal Bedding in static micro-isolators on a 12-hour light cycle at 20-22° C. (68-72° F.) and 40-60% humidity. CR Discovery Services specifically complies with the recommendations of the  Guide for Care and Use of Laboratory Animals  with respect to restraint, husbandry, surgical procedures, feed and fluid regulation, and veterinary care. The animal care and use program at CR Discovery Services is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), which assures compliance with accepted standards for the care and use of laboratory animals. 
 NCI-N87 Xenografts 
 Tumour Cell Culture 
 Human NCI-N87 gastric carcinoma lymphoma cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 units/mL penicillin, 100 pg/mL streptomycin sulfate and 25 pg/mL gentamicin. The cells were grown in tissue culture flasks in a humidified incubator at 37° C., in an atmosphere of 5% CO2 and 95% air. 
 In Vivo Implantation and Tumour Growth 
 The NCI-N87 cells used for implantation were harvested during log phase growth and Re-suspended in phosphate buffered saline (PBS) containing 50% Matrigel™ (BD Biosciences). On the day of tumour implant, each test mouse was injected subcutaneously in the right flank with 1×10 7  cells (0.1 mL cell suspension), and tumour growth was monitored as the average size approached the target range of 100 to 150 mm 3 . Fourteen days later, designated as Day 1 of the study, mice were sorted according to calculated tumour size into groups each consisting of ten animals with individual tumour volumes ranging from 108 to 172 mm 3  and group mean tumour volumes of 133 mm 3 . 
 Tumours were measured in two dimensions using calipers, and volume was calculated using the formula: 
                 ⁢       Tumour   ⁢           ⁢   Volume   ⁢           ⁢     (     mm   3     )       =         w   2     ×   l     2                       where   ⁢           ⁢   w     =       width   ⁢           ⁢   and   ⁢           ⁢   l     =   length       ,     in   ⁢           ⁢   mm     ,     of   ⁢           ⁢   the   ⁢           ⁢     tumour   .           ⁢   Tumour     ⁢           ⁢   weight   ⁢           ⁢   may   ⁢           ⁢   be   ⁢           ⁢   estimated   ⁢           ⁢   with   ⁢           ⁢   the   ⁢           ⁢   assumption   ⁢           ⁢   that   ⁢           ⁢   1   ⁢           ⁢   mg   ⁢           ⁢   is   ⁢           ⁢   equivalent   ⁢           ⁢   to   ⁢           ⁢   1   ⁢           ⁢       mm     3     ⁢           ⁢   of   ⁢           ⁢   tumour   ⁢           ⁢     volume   .             
Treatment
 
 Treatment began on Day 1 in groups of 10 mice (n=10) with established subcutaneous NCI-N87 tumours (108-172 mm 3 ). Trastuzumab-6 was administered intravenously once on Day 1 (qd×1). A vehicle-treated group served as the control group for efficacy analysis. Tumours were measured twice per week until the study was ended on Day 78. Each mouse was euthanized when its tumour reached the endpoint volume of 800 mm 3  or on the final day, whichever came first. The time to endpoint (TTE) was calculated for each mouse. 
 Treatment outcome was determined from percent tumour growth delay (% TGD), defined as the percent increase in median TTE for treated versus control mice, with differences between groups deemed statistically significant at P≤0.05 using logrank survival analysis. Mice were monitored for complete regression (CR) and partial regression (PR) responses. 
 Treatment tolerability was assessed by body weight measurements and frequent observation for signs of treatment-related side effects. Treatment tolerability was assessed by body weight measurements and frequent observation for signs of treatment-related side effects. All regimens were well tolerated. The median TTE for vehicle-treated controls was 45.2 days, establishing a maximum possible TGD of 32.8 days (72%) for the 78-day study. All ADC regimens tested produced significant survival benefit compared to vehicle-treated controls (P<0.01) and eleven of thirteen resulted in the maximum possible TGD. 
 The minimum effective dose was defined as the minimum dosage required to produce tumour stasis for twenty-eight days after test article administration. Based on visual inspection of the mean and median tumour volume plots and percent change of tumour volume from Day 1, trastuzumab-6 at 0.4 mg/kg, appeared to be the dosage that achieved a response consistent with the minimum effective dose 
 Trastuzumab-6 at 0.4 mg/kg produced one partial regression (PR) and at 0.6 mg/kg produced three partial regressions (PRs). The results are illustrated in  FIG. 1 . 
 JIMT-1 Xenografts 
 Tumour Cell Culture 
 JIMT-1 human breast carcinoma cells were grown in DMEM containing 10% fetal bovine serum, 100 units/mL penicillin G sodium, 100 pg/mL streptomycin sulphate, 25 pg/mL gentamicin, and 2 mM glutamine. Cell cultures were maintained in tissue culture flasks in a humidified incubator at 37° C., in an atmosphere of 5% CO02 and 95% air. 
 In Vivo Implantation and Tumour Growth 
 The JIMT-1 cells used for implantation were harvested during exponential growth and re-suspended in 50% Matrigel (BD Biosciences): 50% phosphate buffered saline at a concentration of 5×10′ cells/mL. On the day of tumour implant, each test mouse was injected subcutaneously in the right flank with 1×10′ cells (0.2 mL cell suspension), and tumour growth was monitored as the average size approached the target range of 100 to 150 mm 3 . Tumours were measured in two dimensions using calipers, and volume was calculated using the formula: 
                 ⁢       Tumour   ⁢           ⁢   Volume   ⁢           ⁢     (     mm   3     )       =         w   2     ×   l     2                       where   ⁢           ⁢   w     =       width   ⁢           ⁢   and   ⁢           ⁢   l     =   length       ,     in   ⁢           ⁢   mm     ,     of   ⁢           ⁢   the   ⁢           ⁢     tumour   .           ⁢   Tumour     ⁢           ⁢   weight   ⁢           ⁢   may   ⁢           ⁢   be   ⁢           ⁢   estimated   ⁢           ⁢   with   ⁢           ⁢   the   ⁢           ⁢   assumption   ⁢           ⁢   that   ⁢           ⁢   1   ⁢           ⁢   mg   ⁢           ⁢   is   ⁢           ⁢   equivalent   ⁢           ⁢   to   ⁢           ⁢   1   ⁢           ⁢       mm     3     ⁢           ⁢   of   ⁢           ⁢   tumour   ⁢           ⁢     volume   .             
Treatment
 
 Treatment began on Day 1 in groups of 10 mice (n=10) with established subcutaneous JIMT-1 tumours (75-162 mm 3 ). Trastuzumab-6 was administered intravenously once on Day 1 (qd×1). A vehicle-treated group served as the control group for efficacy analysis. Tumours were measured twice per week until the study was ended on  Day  64. Each mouse was euthanized when its tumour reached the endpoint volume of 1000 mm 3  or on the final day, whichever came first. The time to endpoint (TTE) was calculated for each mouse. 
 Treatment outcome was determined from percent tumour growth delay (% TGD), defined as the percent increase in median TTE for treated versus control mice, with differences between groups deemed statistically significant at P≤0.05 using logrank survival analysis. Mice were monitored for complete regression (CR) and partial regression (PR) responses. 
 Treatment tolerability was assessed by body weight measurements and frequent observation for signs of treatment-related side effects. Treatment tolerability was assessed by body weight measurements and frequent observation for signs of treatment-related side effects. All regimens were well tolerated. The median TTE for vehicle-treated controls was 55.7 days, establishing a maximum possible TGD of 8.3 days (13%) for the 64-day study. All ADC regimens tested produced significant survival benefit compared to vehicle-treated controls (P<0.01) and eleven of thirteen resulted in the maximum possible TGD. 
 The minimum effective dose was defined as the minimum dosage required to produce tumour stasis for twenty-eight days after test article administration. Based on visual inspection of the mean and median tumour volume plots and percent change of tumour volume from Day 1, trastuzumab-6 at 0.3 mg/kg, appeared to be the dosage that achieved a response consistent with the minimum effective dose. 
 Trastuzumab-6 at 0.3 mg/kg produced one partial regression (PR) and at 1.0 mg/kg produced two partial regressions (PRs) and three complete regressions (CRs) which remained tumour-free survivors (TFSs) at study end. The results are illustrated in  FIG. 2 . 
 BT474 Xenografts 
 In Vivo Implantation and Tumour Growth 
 Xenografts were initiated with BT474 human breast carcinomas maintained at CR Discovery Services by serial subcutaneous transplantation in SCID mice. On the day of tumor implant, each test mouse received a 1 mm 3  BT474 fragment implanted subcutaneously in the right flank, and tumor growth was monitored as the average size approached the target range of 100 to 150 mm 3 . Thirty-five days after tumor implantation, designated as Day 1 of the study, the animals were sorted into groups each consisting of ten mice with individual tumor volumes of 75 to 196 mm 3  and group mean tumor volumes of 117-118 mm 3 . Tumors were measured in two dimensions using calipers, and volume was calculated using the formula: 
                 ⁢       Tumour   ⁢           ⁢   Volume   ⁢           ⁢     (     mm   3     )       =         w   2     ×   l     2                       where   ⁢           ⁢   w     =       width   ⁢           ⁢   and   ⁢           ⁢   l     =   length       ,     in   ⁢           ⁢   mm     ,     of   ⁢           ⁢   the   ⁢           ⁢     tumour   .           ⁢   Tumour     ⁢           ⁢   weight   ⁢           ⁢   may   ⁢           ⁢   be   ⁢           ⁢   estimated   ⁢           ⁢   with   ⁢           ⁢   the   ⁢           ⁢   assumption   ⁢           ⁢   that   ⁢           ⁢   1   ⁢           ⁢   mg   ⁢           ⁢   is   ⁢           ⁢   equivalent   ⁢           ⁢   to   ⁢           ⁢   1   ⁢           ⁢       mm     3     ⁢           ⁢   of   ⁢           ⁢   tumour   ⁢           ⁢     volume   .             
Treatment
 
 Treatment began on Day 1 in groups of mice (n=10) with established subcutaneous BT474 tumors (75-196 mm 3 ). Trastuzumab-6 was were administered intravenously once on Day 1 (qd×1) at two dosages (0.3 and 1 mg/kg). The dosing volume was 0.2 mL per 20 grams of body weight (10 mL/kg), and was scaled to the body weight of each individual animal. A vehicle-treated group served as the control group for efficacy analysis. Tumors were measured twice per week until the study was ended on  Day  60. Each mouse was euthanized when its tumor reached the endpoint volume of 1000 mm 3  or on the final day, whichever came first. The time to endpoint (TTE) was calculated for each mouse. 
 Treatment outcome was determined from percent tumor growth delay (% TGD), defined as the percent increase in median TTE for treated versus control mice, with differences between groups deemed statistically significant at P≤0.05 using logrank survival analysis. Mice were monitored for complete regression (CR) and partial regression (PR) responses. Treatment tolerability was assessed by body weight measurements and frequent observation for signs of treatment-related side effects. Treatment tolerability was assessed by body weight measurements and frequent observation for signs of treatment-related side effects. All regimens were acceptably tolerated. The median TTE for vehicle-treated controls was 44.4 days, establishing a maximum possible TGD of 15.6 days (35%) for the 60-day study. 
 The minimum effective dose was defined as the minimum dosage required to produce tumour stasis for twenty-eight days after test article administration. Based on visual inspection of the mean and median tumour volume plots and percent change of tumour volume from Day 1, trastuzumab-6 at 0.3 mg/kg, appeared to be the dosage that achieved a response consistent with the minimum effective dose. 
 Trastuzumab-6 at 0.3 mg/kg produced four partial regressions (PRs) and at 1.0 mg/kg produced seven partial regressions (PRs) and one complete regressions (CR) which remained a tumour-free survivor (TFS) at study end. The results are illustrated in  FIG. 3 . 
 Example 5—Toxicity Studies/Therapeutic Index 
 Rat Study: 
 A single dose toxicity study was used to determine the maximum tolerated dose (MTD) and safety profile of Trastuzumab-6. Male Sprague Dawley rats (Harlan, Inc) were dosed once by slow bolus intravenous injection via the tail vein with vehicle control (25 mM Histidine-HCl, 7% sucrose, 0.02% Polysorbate 80, pH 6.0) or test material (Trastuzumab-6). 
 Parameters evaluated during the study included mortality, physical examinations, cageside observations, body weights, body weight changes, clinical pathology (clinical chemistry, hematology, and coagulation), and gross pathology findings. All animals were terminated on Study Day (SD) 29. 
 
 
 
 
 
 
   
 
 
   
   
   
   
   
 Male Rats 
 
 
   
   
 Dose 
 Dose 
   
 Main Study 
 
 
 Group 
 Treatment 
 Route 
 (mg/kg) 
 Frequency 
 N 
 
 
   
 
 
 
   
 
 
 
 
 1 
 Control 
 IV 
 0 
 Single 
 5 
 
 
 4 
 Trastuzumab-6 
 IV 
 0.5 
 Single 
 5 
 
 
 7 
 Trastuzumab-6 
 IV 
 1.5 
 Single 
 5 
 
 
   
 
 
 Control = 25 mM Histidine-HCl, 7% sucrose, 0.02% Polysorbate 80, pH 6.0 
 
 
 
 
 
 Tolerability was determined based on toxicity end points, including body weight loss (>10%) and bone marrow suppression. Based on minimal adverse findings in the 1.5 mg/kg high dose group, the maximum tolerated dose (MTD) in the rat after a single dose of Trastuzumab-6 was determined to be 0.5 mg/kg. 
 Therapeutic Index 
 The Therapeutic Index can be calculated by dividing the maximum tolerated single dose (MTD) of non-targeted ADC in rat, by the minimal effective single dose (MED) of the a targeted ADC. The MED is the single dose necessary to achieve tumour stasis in an in vivo model at 28 days (for NCI-N87 xenograft). 
 Thus for conjugates of  compound  6, the therapeutic index is the MTD of 0.5 mg/kg divided by the MED which is 0.4 mg/kg (see above), giving a Therapeutic Index of 1.25. 
 All documents and other references mentioned above are herein incorporated by reference. 
 
 
 
 
 
 
 
 
 
